

The logo features a stylized heart shape composed of thick, rounded lines in red and dark blue. The top and right sides are dark blue, while the bottom and left sides are red.

HFSA 2022

ANNUAL SCIENTIFIC MEETING

WHERE HEART FAILURE TEAMS GATHER

Gaylord National Harbor, Washington, DC

September 30 – October 3, 2022

2022

Scientific Session

Book

Session 01 - FDA Special Session: Background Medical Therapy for HF Clinical Trials

SESSION DETAILS

Session Title: FDA Special Session: Background Medical Therapy for HF Clinical Trials

Session Number: Session 01

Session Time: Saturday Oct 1, 2022 1:45 PM - 2:45 PM

Session Locations: Potomac C

Session Description: This session aims to discuss the ideal background drug and device therapy for future HF trials, with the growing number of approved drugs and devices. This is the official FDA designated special focus session.

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 1:45PM - 1:45PM.

Moderator

James Januzzi. Massachusetts General Hospital, Wellesley, MA

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Ileana Piña. Albert Einstein College of Medicine, Cleveland Heights, OH

Saturday, October 1 1:45PM - 1:55PM.

Basic Necessities for HFrEF and the New Standard for HFpEF

Scott Solomon. Mass General Brigham

Saturday, October 1 1:55PM - 2:00PM.

New Drugs - SGLT2 inhibitors

John McMurray. Cardiovascular Research Centre

Saturday, October 1 2:05PM - 2:10PM.

New Drugs - Vericiguat

Christopher O'Connor. Inova Health System

Saturday, October 1 2:10PM - 2:15PM.

Standard Background Device Therapy

JoAnn Lindenfeld. Vanderbilt University Health, Nashville, TN

Saturday, October 1 2:05PM - 2:10PM.

Using a GDMT Score

Mona Fiuzat. Duke University School of Medicine

Saturday, October 1 2:15PM - 2:20PM.

FDA Perspective – CDRH

Bram Zuckerman. Department of Health & Human Services

Saturday, October 1 2:20PM - 2:25PM.

Speaker - FDA Perspective - CDER, DCN

Charu Gandotra. FDA Center for Drug Evaluation and Research, Silver Spring, MD

Saturday, October 1 2:25PM - 2:45PM.

Audience Q&A / Panel Discussion

Session 02 - #ConstructivelyDisruptive at JCF

SESSION DETAILS

Session Title: #ConstructivelyDisruptive at JCF

Session Number: Session 02

Session Time: Saturday Oct 1, 2022 1:45 PM - 2:45 PM

Session Locations: Potomac D

Session Description: A session highlighting recent and ongoing Journal of Cardiac Failure initiatives that align with the HFSA mission focused on multi-disciplinary engagement; diversity, equity, inclusion, and belonging; educational efforts in academic publishing; and the transformational power of language, and profiling 3 selected high impact papers in JCF over the past year. There will be 4 talks followed by 5 minutes of discussion with a multidisciplinary multinational panel comprised of nursing, pharmacy, physician experts.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Describe key examples of how words matter in our discussion with and about patients living with heart failure.
- Recognize how papers have the power to represent institutional/cultural change in clinical care and practice.
- Explain the importance of constructive discourse using journal platforms to advance our understanding and practice of medicine in heart failure.

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Robert Mentz. Duke University Health, Durham, North Carolina, NC

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Randall Starling. Cleveland Clinic Main Campus

Saturday, October 1 1:45PM - 2:00PM.

Words Matter — Failure to Function, Barriers to Adherence, and Shift from Candidacy to Benefit Derived

Anuradha Lala. Mount Sinai, New York, NY

Reporting on the rationale and insights learned from the Words Matter Movement at the Journal of Cardiac Failure. Describe key examples of how words matter in our discussion with and about patients living with heart failure, with specific input and examples from a patient(s)

Saturday, October 1 2:00PM - 2:15PM.

Why You Should Read JCF – The multidisciplinary and multinational perspective

Colleen McIlvennan. The University of Colorado Health, Denver, CO

As the official journal for the HFSA, JCF is uniquely advantaged by serving as a platform for dissemination of research and perspective by nursing, physician, pharmacist, patient, patient partners living with heart failure. Here we discuss the value of multidisciplinary and cross cultural research and initiatives and describe how they were put into practice

Saturday, October 1 2:15PM - 2:30PM.

Rapid Fire - The Best of JCF

Robert Mentz. Duke University Health, Durham, North Carolina, NC

Sharing high impact papers over the past year

Saturday, October 1 2:30PM - 2:45PM.

Audience Q&A / Panel Discussion

Session 03 - Medical Therapy of Heart Failure with Reduced Ejection Fraction: New Guidelines and Evolving Clinical Practice

SESSION DETAILS

Session Title: Medical Therapy of Heart Failure with Reduced Ejection Fraction: New Guidelines and Evolving Clinical Practice

Session Number: Session 03

Session Time: Saturday Oct 1, 2022 1:45 PM - 3:00 PM

Session Locations: National Harbor 2/3

Session Description: This session will provide a comprehensive overview of the treatment of HFrEF including guideline updates from the newly published 2022 guideline. The focus will be on specific updates on pharmacotherapy in HFrEF, including initiating and titrating GDMT with the 4 medication classes, and discussing potential barriers. Patient case examples with audience participation will be incorporated to highlight specific issues with GDMT initiation in stable vs. unstable (outpatient vs. inpatient) scenarios.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Discuss updates in the new HF guidelines focusing on pharmacotherapy and initiating and titrating GDMT for HFrEF.
- Describe when and how second-line therapies (i.e., ivabradine, vericiguat, PUFAs, digoxin) should be integrated into the management of HFrEF.
- Explain practical strategies for mitigating potential barriers to initiating GDMT such as insurance coverage, formulary status, and cost of medications.

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Amanda Vest. Tufts Medical Center

Saturday, October 1 1:45PM - 2:00PM.

A Changing Paradigm for HFrEF: Key Updates From the 2022 HFSA/AHA/ACC Guidelines

Biykem Bozkurt. Baylor College of Medicine, Houston, TX

This session will provide a brief update of key pharmacotherapeutic changes to the 2022 guidelines, highlighting key takeaways and variance with recently published ESC guidelines.

Saturday, October 1 2:00PM - 2:15PM.

2b or not 2b, that is the question

Michelle Kittleson. Cedars-Sinai Medical Center

This session will highlight areas of controversy in the development of the guideline and provide context for the decisions ultimately made by the guidelines committee for the final document. Areas of disagreement with the 2021 ESC Guidelines Could Also be Emphasized Here

Saturday, October 1 2:15PM - 2:30PM.

Implementing GDMT for HF with Reduced EF: Challenges and Opportunities

Orly Vardeny. The University of Minnesota Medical School, Minneapolis, MN

This talk will focus on strategies for successful implementation of GDMT including strategies for sequencing, in-hospital initiation, use of pharmacists/patient navigators and 'GDMT clinics', and strategies for overcoming cost barriers

Saturday, October 1 2:30PM - 2:45PM.

Horizon Therapies for HF: How will we fit them in?

TBD

Integration of second-line therapies (vericiguat, digoxin, potassium binders) and potential role of horizon treatments including omecamtiv mecarbil/finerenone.

Saturday, October 1 2:45PM - 3:00PM.

Audience Q&A / Panel Discussion

Session 04 - Dangerous Liaisons – Cardio-oncology

SESSION DETAILS

Session Title: Dangerous Liaisons – Cardio-oncology

Session Number: Session 04

Session Time: Saturday Oct 1, 2022 1:45 PM - 3:00 PM

Session Locations: National Harbor 10/11

Session Description: This session highlights recent advances in the emerging field of cardio-oncology. It includes four presentations. Each speaker will have 10 or 12 minutes to present followed by 14 minutes for Q & A at the end of the session.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Discuss the relationship between cardiovascular disease and cancer.
- Describe left ventricular dysfunction related to oral cancer therapies, immune checkpoint inhibitors and CAR-T cell therapies.
- Evaluate drug-drug interactions common to cardiovascular and oncologic therapeutics.

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Brian Jensen. University of North Carolina at Chapel Hill, Chapel Hill, NC

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Jo Ellen Rodgers. The University of North Carolina at Chapel Hill, Chapel Hill, NC

Saturday, October 1 1:45PM - 1:57PM.

Reverse Cardio-Oncology - Does Cardiovascular Disease Potentiate Cancer?

Aarti Aasnani. Beth Israel Deaconess Medical Center, Boston, MA

Discusses the relationships between cancer & cancer therapies with the development/worsening of CVD and how CVD may contribute to cancer.

Saturday, October 1 1:57PM - 2:09PM.

Don't Go Breaking My Heart! LV Dysfunction related to Oral Cancer Therapies and the Role of GDMT

Anita Deswal. The University of Texas MD Anderson Cancer Center, Houston, TX

Briefly acknowledge role of anthracyclines and HER2-targeted therapies in the development of left ventricular (LV) dysfunction. Then more deeply explore the incidence, screening/detection and presentation of LV dysfunction with oral cancer therapies. Also address the role of guideline directed medical therapies in prevention/treatment of LV dysfunction and if/when to hold cancer therapy.

Saturday, October 1 2:09PM - 2:21PM.

Check It Out! LV Dysfunction Related to Immune Checkpoint Inhibitors and CAR-T Cell Therapies

Ronald Witteles. Stanford University, Stanford, CA

Discuss the incidence, presentation and management of left ventricular dysfunction associated with both immune checkpoint inhibitors and CAR-T cell therapies .

Saturday, October 1 2:21PM - 2:33PM.

The Alphabet Soup of Drug-Drug Interactions in Cardio-oncology

Craig Beavers. University of Kentucky, Lexington, KY

Review of both pharmacodynamic and pharmacokinetic drug-drug interactions specific to cardio- oncology with emphasis on cardiovascular and oncology therapeutics. A brief acknowledgement of other supportive therapies is allowable. As time allows, also include examples of alternative therapies and/or management strategies (e.g., dose reduction/ other).

Saturday, October 1 2:33PM - 2:45PM.

Rescue Me: Role of medical, device, and advanced HF therapies including transplant in cancer survivors

Bhavadarini Ramu. Medical University of South Carolina Health

Saturday, October 1 2:45PM - 3:00PM.

Audience Q&A / Panel Discussion

Session 05 - Many Roads Lead to Rome: Evolving Training Pathways for the Advanced Heart Failure and Critical Care Cardiologist

SESSION DETAILS

Session Title: Many Roads Lead to Rome: Evolving Training Pathways for the Advanced Heart Failure and Critical Care Cardiologist

Session Number: Session 05

Session Time: Saturday Oct 1, 2022 1:45 PM - 3:00 PM

Session Locations: National Harbor 4/5

Session Description:

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Explain evolution of cardiac critical care.
- Describe training pathways for physicians, nurses, and pharmacists.
- Discuss how to improve training for multidisciplinary care in the future.

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Sara Paul. Hickory, NC

Saturday, October 1 1:45PM - 1:45PM.

Moderator

Vanessa Blumer. Cleveland Clinic, Cleveland, OH

Saturday, October 1 1:45PM - 1:57PM.

It's No Longer Your Grandma's Unit - The Impact of Advanced Heart Failure in Today's Cardiac ICU

Ann Gage. HCA Healthcare, Nashville, TN

Saturday, October 1 1:57PM - 2:09PM.

Do As I Say, Not as I Did - How I Might Train Differently This Time Around for Critical Care

Jason N. Katz. Duke University, Durham, NC

Saturday, October 1 2:09PM - 2:21PM.

How Advanced HF Physicians Can Learn to Manage Critically Ill Patients During Training

Rachna Kataria. Massachusetts General Hospital/Harvard Medical School, Boston, MA

Saturday, October 1 2:21PM - 2:33PM.

Training Pathways for Advanced Practice Providers in Advanced HF

Shannon Cornell. Medical University of South Carolina, Charleston, SC

Saturday, October 1 2:33PM - 2:45PM.

Moving from the Basement to the Cardiac ICU: Advancing the Practice of Pharmacy in HF

Robert Page. UC Denver, Denver, CO

Saturday, October 1 2:45PM - 3:00PM.

Audience Q&A / Panel Discussion

Session 06 - Women in Heart Failure: What are the Opportunities?

SESSION DETAILS

Session Title: Women in Heart Failure: What are the Opportunities?

Session Number: Session 06

Session Time: Saturday Oct 1, 2022 3:15 PM - 4:15 PM

Session Locations: Potomac C

Session Description: This session will highlight the opportunities to improve the experience of and foster the career development of women professionals providing care for patients with heart failure.

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Kerry Pickworth. The Ohio State University

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Michelle Weaver. The Ohio State University

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Sarine Beukian. NewYork-Presbyterian/Columbia University Irving Medical Center

Saturday, October 1 3:15PM - 3:25PM.

The Power of Mentoring: A Mentee's Perspective

Ersilia DeFilippis. NewYork - Presbyterian Medical Group, New York, NY

Recognize the importance of the mentor-mentee relationship in career success

Saturday, October 1 3:25PM - 3:35PM.

Success in Research & Publication for WHF: the Role of Journal of Cardiac Failure

Anuradha Lala. Mount Sinai, New York, NY

Identify models of success in research and publication for WHF and the role of JCF in this effort

Saturday, October 1 3:35PM - 3:45PM.

Childbearing Among Women in Heart Failure: The Price & Prejudice

Mahazarin Ginwalla. Sutter Health, Burlingame, CA

Understand opportunities for improvement and strategies for coping in the workplace in regards to pregnancy and child rearing for WHF

Saturday, October 1 3:45PM - 3:55PM.

Climbing up the ladder: How to navigate the steps?

Nancy Albert. Cleveland Clinic, Chesterland, OH

Identify pathways and share tips for development as a leader for WHF

Saturday, October 1 3:55PM - 4:05PM.

Diversity and Inclusion: How do we walk the talk?

Khadijah Breathett. Indiana University School of Medicine, Indianapolis, IN

Discuss practical steps towards inclusion and diversity in the workforce

Saturday, October 1 4:05PM - 4:15PM.

Audience Q&A / Panel Discussion

Session 07 - Mission Impossible: Challenging Cardiogenic Shock Cases

SESSION DETAILS

Session Title: Mission Impossible: Challenging Cardiogenic Shock Cases

Session Number: Session 07

Session Time: Saturday Oct 1, 2022 3:15 PM - 4:15 PM

Session Locations: Potomac D

Session Description: Despite remarkable technological and medical advances in the management of cardiogenic shock, associated mortality and morbidity remain exceedingly high. This is especially true in patients with more unique anatomy and pathophysiology who present with shock. This session will focus on discussing the management of cardiogenic shock in medically, anatomically, and pathophysiologically complex patient populations, as illustrated by specific case presentations.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Review support strategies for patients with restrictive cardiomyopathy and cardiogenic shock.
- Discuss management of patients with pulmonary embolism complicated by cardiogenic shock.

- Discuss management of patients presenting with cardiogenic shock and ventricular tachycardia, complex anatomy, or biventricular failure.

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Esther Vorovich. Northwestern University Feinberg School of Medicine

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Emily Benton. The University of Colorado Health

Saturday, October 1 3:15PM - 3:22PM.

Stiff As a Board: Shock in Restrictive Cardiomyopathy

Kunal Bhatt. Emory University - Healthcare

The 7 min case should briefly introduce the pertinent patient information and an initial treatment plan. The panel of speakers and moderators will discuss the plan for 5 minutes following the case.

Saturday, October 1 3:22PM - 3:27PM.

Case Discussion - Panel (5 min)

Saturday, October 1 3:27PM - 3:34PM.

Switched at birth: Shock in a Congenital Heart Patient

Mirnela Byku. University of North Carolina at Chapel Hill

The 7 min case should briefly introduce the pertinent patient information and an initial treatment plan. Consider choosing an adult congenital patient case. The panel of speakers and moderators will discuss the plan for 5 minutes following the case.

Saturday, October 1 3:34PM - 3:39PM.

Case Discussion - Panel (5 min)

Saturday, October 1 3:39PM - 3:46PM.

Massive PE – Medical and Interventional Therapies

Yevgeniy Brailovsky. Thomas Jefferson University, Philadelphia, PA

The 7 min case should briefly introduce the pertinent patient information for a massive PE leading to CV shock and an initial treatment plan. The panel of speakers and moderators will discuss the plan for 5 minutes following the case.

Saturday, October 1 3:46PM - 3:51PM.

Case Discussion - Panel (5 min)

Saturday, October 1 3:51PM - 3:58PM.

Shocking It May Be: Managing VT Storm

David Baran. Sentara

The 7 min case should briefly introduce the pertinent patient information for a patient with VT storm and CV shock and an initial treatment plan. The panel of speakers and moderators will discuss the plan for 5 minutes following the case.

Saturday, October 1 3:58PM - 4:03PM.

Case Discussion - Panel (5 min)

Saturday, October 1 4:03PM - 4:10PM.

Fatal Attraction: Biventricular Shock and Contemporary Strategies

Filio Billia. University Health Network

The 7 min case should briefly introduce the pertinent patient information for a patient with biventricular shock and an initial treatment plan. The panel of speakers and moderators will discuss the plan for 5 minutes following the case.

Saturday, October 1 4:10PM - 4:15PM.

Case Discussion - Panel (5 min)

Session 08 - Hypertrophic Cardiomyopathy: It's a New Dawn...And I'm Feeling Good

SESSION DETAILS

Session Title: Hypertrophic Cardiomyopathy: It's a New Dawn...And I'm Feeling Good

Session Number: Session 08

Session Time: Saturday Oct 1, 2022 3:15 PM - 4:15 PM

Session Locations: National Harbor 2/3

Session Description: This will be used in the meeting app for session attendees. This session will provide a contemporary update for care of the Hypertrophic Cardiomyopathy patient. The underlying genetics, clinical trial results of myosin inhibitors, and care for the end-stage HCM patient will be points of emphasis. Keywords: Hypertrophic cardiomyopathy, sarcomere, myosin inhibitors, mavacamten.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Highlight new scientific insights into HCM pathophysiology. Outline evolving role of myosin inhibitors in treatment of HCM.
- Review practical guidance for exercise prescription and risk stratification for sudden death.
- Discuss updated guideline recommendations for management of patients with HCM.

FULL SESSION DETAILS – Speakers subject to change

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Nosheen Reza. The University of Pennsylvania Health System, Philadelphia, PA

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Ian Hollis. The University of North Carolina at Chapel Hill

Saturday, October 1 3:15PM - 3:30PM.

Contemporary Insights from HCM Genetics: Heading for Personalized Medicine?

Victoria Parikh. Stanford University

Current understanding of pathogenic mutations, sarcomere vs non-sarcomere mutations. Risk prediction/prognosis based on genetic mutation. Genotype/phenotype relationships.

Saturday, October 1 3:30PM - 3:45PM.

Medical Therapy for HCM: Are Myosin Inhibitors a Game-Changer?

Carolyn Ho. Brigham and Women's Hospital/Harvard Medical School

Include brief review of current medical therapy (cardioselective beta-blocker, calcium channel blocker, disopyramide). Focus on recent trials investigating myosin inhibitors in both obstructive and nonobstructive HCM. Discussion how myosin inhibitors will fit into current treatment algorithms.

Saturday, October 1 3:45PM - 4:00PM.

Exercise Prescription and Risk Stratification for Sudden Death: Just Bowling and Archery?

Sharlene Day. University of Pennsylvania

Provide practical guidance for exercise prescription in HCM. Review HCM guideline updates re: exercise and sudden death risk assessment. Consider adding challenging case discussion.

Saturday, October 1 4:00PM - 4:15PM.

Management of End-stage HCM: Options for Salvage Therapy?

Marton S. Maron. Tufts University School of Medicine, Boston, MA

Timing of referral for invasive management. Treatment for the nonobstructive NYHA class III patient. When to consider advanced HF therapies, discussion of current UNOS listing guidelines

Session 09 - New Device Based Therapies for HF

SESSION DETAILS

Session Title: New Device Based Therapies for HF

Session Number: Session 09

Session Time: Saturday Oct 1, 2022 3:15 PM - 4:15 PM

Session Locations: National Harbor 10/11

Session Description: This session will focus on new device-based therapies for patients with heart failure.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Identify what device therapies can be used to improve patient QOL and outcomes. Review future innovations in LVAD and EP-based devices.
- Discuss atrial shunting devices in the treatment of HF.

FULL SESSION DETAILS – Speakers subject to change

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Jacob Abraham. Providence Health and Services, Portland, OR

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Marat Fudim. Duke University Health, Durham, NC

Saturday, October 1 3:15PM - 3:27PM.

What Can Device Therapies Bring to the Table?

Rebecca Cogswell. The University of Minnesota Medical School, Minneapolis, MN

Atrial Shunt Devices for the Treatment of Heart Failure

Sanjiv Shah. Northwestern University Feinberg School of Medicine, Chicago, IL

1. Physiology of atrial shunt devices for the treatment of heart failure and review primary results of the REDUCE LAP-HF II trial (results published in the Lancet).2. Subgroups: responders (peak exercise PVR < 1.74); Pacemakers and atrial fibrillation subgroups; Sex3. Next steps: what's needed now, veracity of 'responder', confirmatory trial description

Saturday, October 1 3:39PM - 3:51PM.

Designing the Perfect LVAD Pump: Engineering a Way to Decrease Bleeding

Mark Slaughter. The University of Louisville Health, Louisville, KY

Saturday, October 1 3:51PM - 4:03PM.

Invasive device-based therapies: what's in the pipeline

Navin Kapur. Tufts Medical Center, Hanover, MA

Saturday, October 1 4:03PM - 4:15PM.

Audience Q&A / Panel Discussion

Session 10 - Nutrition and Obesity Management in Heart Failure

SESSION DETAILS

Session Title: Nutrition and Obesity Management in Heart Failure

Session Number: Session 10

Session Time: Saturday Oct 1, 2022 3:15 PM - 4:15 PM

Session Locations: National Harbor 4/5

Session Description: This session will discuss the most recent evidence related to the role of nutrition and obesity in patients with heart failure. Specifically, this session will provide crucial insights on the role of dietary sodium, dietary fats, and overall dietary patterns, such as the Mediterranean diet, ketogenic diet, and DASH diet, in patients with elevated risk, and

with established heart failure, with and without malnutrition. The impact of therapies to manage obesity and modify risk from dietary patterns.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Identify the role of nutrition for patients with heart failure.
- Describe specific diets and their role in heart failure patients with and without malnutrition.
- Demonstrate specific assessment skills to improve outcomes in patients with obesity and heart failure

FULL SESSION DETAILS – *Speakers subject to change*

Saturday, October 1 3:15PM - 3:15PM.

Moderator

Windy Alonso. The University of Nebraska Medical Center

Moderator

Amanda Vest. Tufts Medical Center

Saturday, October 1 3:15PM - 3:25PM.

How Much Sodium is Enough: We Finally Have an Answer

Justin Ezekowitz. University of Alberta Cardiovascular Research Institute, Alberta, AB, Canada

This talk will present the evidence of dietary sodium in heart failure. Specifically, the results of SODIUM-HF trial will be presented

Saturday, October 1 3:25PM - 3:35PM.

The 'Goods and the 'Bads': The Role of Dietary Fats in Heart Failure

Salvatore Carbone. Virginia Commonwealth University

This talk will discuss the evidence relate to dietary fats in preventing CVD and to treat patients with established heart failure.

Saturday, October 1 3:35PM - 3:45PM.

Weight Loss Pharmacotherapy for Treatment of Heart Failure: It's a Cardiology Problem

Sheldon Litwin. MUSC, Charleston, SC

Saturday, October 1 3:45PM - 3:55PM.

Malnutrition and Dietary Patterns in Heart Failure: We need a Greater EFFORT!

Scott Hummel. University of Michigan Health System

The presentation will discuss the role of malnutrition in heart failure and the results of the RCT EFFORT Trial

Saturday, October 1 3:55PM - 4:05PM.

Is Obesity an Independent Risk Factor for Heart Failure

Ambarish Pandey. UT Southwestern Medical Center

Role of obesity on the risk for heart failure its mediation through reduced cardiorespiratory fitness and metabolic abnormalities and the role of weight loss medication in heart failure including GLP1 receptor agonists agents.

Saturday, October 1 4:05PM - 4:15PM.

Audience Q&A / Panel Discussion

Session 11 - JNC New Investigator Award

SESSION DETAILS

Session Title: JNC New Investigator Award

Session Number: Session 11

Session Time: Sunday Oct 2, 2022 9:45 AM - 10:45 AM

Session Locations: Potomac D

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 9:45AM - 9:45AM.

Moderator

John Burnett, Jr.. Mayo Clinic, Rochester, MN

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Jennifer Cook. Itamar Medical, Tucson, AZ

Sunday, October 2 9:45AM - 9:54AM.

Combining VA-ECMO And Impella (EC-Pella) Before Reperfusion Mitigates Left Ventricular Loading And Injury Due To VA-ECMO In Acute Myocardial Infarction

Kay Everett. Tufts Medical Center

Sunday, October 2 9:54AM - 9:57AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 9:57AM - 10:06AM.

Neighborhood Socioeconomic Status Is Associated With Heart Failure And All-Cause Readmission Within A Safety-Net System

Diane Jeon. University of California, San Francisco, San Francisco, CA

Sunday, October 2 10:06AM - 10:09AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 10:09AM - 10:18AM.

Machine Learning Identification Of Transcriptomics And Clinical Characteristics Associated With Myocardial Recovery In Heart Failure Patients Undergoing Mechanical Circulatory Support

Christos Kyriakopoulos. The University of Utah School of Medicine, Salt Lake City, UT

Sunday, October 2 10:18AM - 10:21AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 10:21AM - 10:30AM.

Cystatin C Versus Creatinine-Based Assessment Of Kidney Function In Patients With Heart Failure And Reduced Ejection Fraction: Insights From PARADIGM-HF

Alberto Pansino. New York - Presbyterian Medical Group, New York, NY

Sunday, October 2 10:30AM - 10:33AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 10:33AM - 10:42AM.

Phase Angle, A Measure Of Skeletal Muscle Quality, Predicts Cardiorespiratory Fitness In Heart Failure With Preserved Ejection Fraction.

Hannah Salmons. Virginia Commonwealth University, Richmond, VA

Sunday, October 2 10:42AM - 10:45AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 9:45AM - 9:45AM.

Judge

Nancy Sweitzer. Washington University in St. Louis, St. Louis, AZ

Sunday, October 2 9:45AM - 9:45AM.

Judge

Benjamin Van Tassell. Virginia Commonwealth University, Richmond, VA

Sunday, October 2 9:45AM - 9:45AM.

Judge

James Januzzi. Massachusetts General Hospital, Wellesley, MA

Sunday, October 2 9:45AM - 9:45AM.

Judge

Walter Koch. Philadelphia, PA

Sunday, October 2 9:45AM - 9:45AM.

Judge

Larry Allen. The University of Colorado Health, Denver, CO

Session 12 - Heart Transplant Allocation in 2022

SESSION DETAILS

Session Title: Heart Transplant Allocation in 2022

Session Number: Session 12

Session Time: Sunday Oct 2, 2022 9:45 AM - 10:45 AM

Session Locations: National Harbor 2/3

Session Description: This session will focus on the state of the heart transplant allocation system in the US in 2022, ranging from a comparative analysis of other countries' policies, future changes in our system, ethical dilemmas, current patient evaluations structures, and decision making.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Explain how the US heart transplant system compares with other countries.
- Examine psychosocial evaluations and multidisciplinary meetings and their roles in organ allocation.
- Discuss future changes in the 2022 heart transplant allocation system.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 9:45AM - 9:45AM.

Moderator

James Fang. The University of Utah Health, Salt Lake City, UT

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Wai Hong Tang. Cleveland Clinic Main Campus, Gates Mills, OH

Sunday, October 2 9:45AM - 9:55AM.

What We Can Learn from International Allocation Systems

Maryjane Farr. UT Southwestern Medical Center, Dallas, TX

Sunday, October 2 9:55AM - 10:05AM.

Current Tweaks and Works in Progress in the US Heart Transplant Allocation System

Shelley Hall. Baylor Scott & White Health, Dallas, TX

Sunday, October 2 10:05AM - 10:15AM.

Evolving Ethical Dilemmas in the US Heart Transplant Allocation System

Savitri Fedson. Baylor College of Medicine, Houston, TX

Sunday, October 2 10:15AM - 10:25AM.

Psychosocial Evaluations in Solid Organ Transplantation - Equity & Inclusion

Keren Ladin. Tufts University, Somerville, MA

Sunday, October 2 10:25AM - 10:35AM.

Multidisciplinary Meetings and their Role in Transplant Allocation

Gregory Ewald. Washington University School of Medicine in St. Louis, Saint Louis, MO

Sunday, October 2 10:35AM - 10:45AM.

Audience Q&A / Panel Discussion

Session 13 - Novel Device Therapies in Heart Failure with Reduced Ejection Fraction

SESSION DETAILS

Session Title: Novel Device Therapies in Heart Failure with Reduced Ejection Fraction

Session Number: Session 13

Session Time: Sunday Oct 2, 2022 9:45 AM - 10:45 AM

Session Locations: National Harbor 10/11

Session Description: This session focuses on the availability of FDA approved, non-LVAD device therapies in the management of heart failure and an update on devices in the pipeline (not yet FDA approved).

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Highlight emerging device therapies for HF.
- Explain the concept for the use of baroreflex activation therapy in heart failure.
- Review options for remote cardiac monitoring and evidence supporting ambulatory hemodynamic management.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Lauren Cooper. Northwell Health, New Hyde Park, NY

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Corrine Jurgens. Boston College

Sunday, October 2 9:45AM - 9:57AM.

Ambulatory Hemodynamic Monitoring: Ready for Prime Time?

J. Thomas Heywood. Scripps Health

Update on GUIDE-HF and trials of implantable hemodynamic monitoring. Discuss appropriate patient selection/cost effectiveness.

Sunday, October 2 9:57AM - 10:09AM.

Horizons in Remote HF Monitoring: Newer Approaches

Jan Griffin. Columbia University, New York, NY

Discuss role of novel remote monitoring approaches. Include device integrated sensors (e.g. Multisense) and Wearables.

Sunday, October 2 10:09AM - 10:21AM.

Novel Devices for Decongestion

Jeffrey Testani. Yale University Medical Center

Discuss novel device-based approaches to decongestive therapy in HF

Sunday, October 2 10:21AM - 10:33AM.

Devices for Modulation of Autonomic Control

Faiez Zannad. Institut du et des Viasseaux, ChU Brabois, France

Address data and potential role for neuromodulation with baroreflex stimulation. Review data supporting cardiac contractility modulation and potential therapeutic role.

Sunday, October 2 10:33AM - 10:45AM.

Audience Q&A / Panel Discussion

Session 14 - Our Hearts Will Go On - What We Learned From COVID-19 and How We Move Forward

SESSION DETAILS

Session Title: Our Hearts Will Go On - What We Learned From COVID-19 and How We Move Forward

Session Number: Session 14

Session Time: Sunday Oct 2, 2022 9:45 AM - 10:45 AM

Session Locations: National Harbor 4/5

Session Description: This session highlights lessons learned from the COVID-19 pandemic and how the heart failure care landscape is forever changed in its wake. There will be 5 10-minute presentations including a case example followed by a 10-minute panel discussion.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Describe the consequences of COVID-19 in HF including clinical care, transplant, and research.
- Examine health disparities in HF care exacerbated by COVID-19. Evaluate vaccine-associated myocarditis.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Andreas Kalogeropoulos. Stony Brook Medicine, Stony Brook, NY

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Heidi Brink. Nebraska Medicine Bellevue Health Center

Sunday, October 2 9:45AM - 9:55AM.

No justice, no peace: Exacerbating Disparities in HF Care

Alanna Morris. Emory University - Healthcare, Atlanta, GA

This session will describe how COVID-19 exacerbated disparities in HF care and discuss strategies for mitigating these disparities.

Sunday, October 2 9:55AM - 10:05AM.

Total Eclipse of the Heart: How COVID-19 permanently changed research and clinical care

Mitchell Psofka. Inova Health System

The COVID-19 pandemic changed the landscape of HF research and clinical care. This presentation will describe the lessons learned and lasting changes in our practice and research.

Sunday, October 2 10:05AM - 10:15AM.

Heaven can wait: Considerations for waitlisted candidates and donor hearts during the pandemic

Laura Peters. The University of Colorado Health

This presentation will discuss how COVID-19 impacted waitlisted candidates and the selection of donor hearts. Strategies for handling incidental positive COVID-19 findings will be discussed.

Sunday, October 2 10:15AM - 10:25AM.

The Long and the Short of COVID Cardiac Injury

Emily Tsai. Columbia University Irving Medical Center, New York, NY

This presentation will discuss the incidence, potential mechanisms, and implications of myocarditis following viruses and vaccine administration

Sunday, October 2 10:25AM - 10:45AM.

Audience Q&A / Panel Discussion

Session 15 - Nursing New Investigator Award Competition

SESSION DETAILS

Session Title: Nursing New Investigator Award Competition

Session Number: Session 15

Session Time: Sunday Oct 2, 2022 11:00 AM - 12:00 PM

Session Locations: Potomac D

Session Description:

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Laura Peters. The University of Colorado Health, Denver, CO

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Melissa Owen. Emory University, Atlanta, GA

Sunday, October 2 11:00AM - 11:09AM.

Unmet Palliative Care Needs And Quality Of Life Of Physically Frail Adults With Heart Failure

Lyndsay DeGroot. Johns Hopkins School of Nursing, Baltimore, MD

Sunday, October 2 11:09AM - 11:12AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 11:12AM - 11:21AM.

Lower Diastolic Blood Pressure Is A Predictor Of Delayed Diuretic Time

Dillon Dzikowicz. University of Rochester, Rochester, NY

Sunday, October 2 11:21AM - 11:24AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 11:24AM - 11:33AM.

Chronic Intravenous Inotropic Support As Bridge To Surgical Therapies In Patients With Sarcoidosis-related Cardiomyopathy

Johana Fajardo. Medstar Washington Hospitale Center, Washington, DC

Sunday, October 2 11:33AM - 11:36AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 11:45AM - 11:54AM.

Does Diet Monotony Mediate The Association Of Financial Status With Dietary Micronutrient Insufficiency In Patients With Heart Failure

JungHee Kang. The University of Kentucky, Lexington, KY

Sunday, October 2 11:54AM - 11:57AM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 11:48AM - 11:57AM.

Snakchat: An Innovative Pathway To Reduce Potassium Intake And Optimize Gdmt

Stella Kozusko. Toronto, ON, Canada

Sunday, October 2 11:57AM - 12:00PM.

Q&A from Judges and Moderators (3 min)

Sunday, October 2 11:00AM - 11:00AM.

Judge

Windy Alonso. The University of Nebraska Medical Center, Omaha, NE

Sunday, October 2 11:00AM - 11:00AM.

Judge

Margaret Cuomo. New York, NY

Sunday, October 2 11:00AM - 11:00AM.

Judge

Teri Diederich. Nebraska Medicine Bellevue Health Center, Omaha, NE

Sunday, October 2 11:00AM - 11:00AM.

Judge

Martha Abshire. Johns Hopkins University, Eldersburg, MD

Sunday, October 2 11:00AM - 11:00AM.

Judge

Robert Malloy. San Francisco Veterans Affairs Health Care System, San Francisco, CA

Session 16 - New Concepts and Controversies in Pulmonary Hypertension and Right Ventricular Failure

SESSION DETAILS

Session Title: New Concepts and Controversies in Pulmonary Hypertension and Right Ventricular Failure

Session Number: Session 16

Session Time: Sunday Oct 2, 2022 11:00 AM - 12:00 PM

Session Locations: Potomac C

Session Description: This session will evaluate right heart function, discuss emerging concepts, and provide guidance on the management of right heart dysfunction and pulmonary hypertension.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Describe the relationship between hepatic congestion/injury and patient outcomes in pulmonary hypertension.
- Describe available therapies for managing acute Right heart failure in the ICU.
- Discuss the mechanisms of liver injury in Right Heart Failure and Pulmonary Hypertension

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Emily Tsai. Columbia University Irving Medical Center, New York, NY

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Kristen Pogue. University of Michigan, Ann Arbor, MI

Sunday, October 2 11:00AM - 11:11AM.

Clinical management of the liver-heart axis in pulmonary hypertension

Sonja Bartolome. UT Southwestern, Dallas, TX

Sunday, October 2 11:11AM - 11:22AM.

Hepatic injury and inflammation in right heart failure: mechanisms and consequences

Joel Schilling. Washington University School of Medicine in St. Louis, Saint Louis, MO

Sunday, October 2 11:22AM - 11:33AM.

Rescuing the failing RV in the ICU - recovery versus replacement

Varinder Randhawa. Cleveland Clinic Main Campus, Cleveland, OH

Sunday, October 2 11:33AM - 11:44AM.

Emerging device therapies for RV failure in pulmonary hypertension

Marc Simon. The University of California - San Francisco Health, San Francisco, CA

Sunday, October 2 11:44AM - 12:00PM.

Audience Q&A / Panel Discussion

Session 17 - Is the Hospital of the Future in Your Living Room? Acute Care Hospital at Home

SESSION DETAILS

Session Title: Is the Hospital of the Future in Your Living Room? Acute Care Hospital at Home

Session Number: Session 17

Session Time: Sunday Oct 2, 2022 11:00 AM - 12:00 PM

Session Locations: National Harbor 2/3

Session Description: Hospital at home programs make acute, hospital-level care available to adults where they live, rather than in a traditional hospital setting. Interest in hospital at home and its patient-centered and cost-effective approach to improving outcomes, particularly for vulnerable patients, has exploded with the COVID-19 pandemic. When the Covid-19 epidemic intensified and hospitals were meeting or exceeding capacity, the U.S. Centers for Medicare & Medicaid Services (CMS) used its emergency authority to waive several regulations. The Acute Hospital Care at Home (AHCaH) initiative, launched in November 2020, allowed Medicare-certified hospitals to treat patients with inpatient-level care at home. Dozens of hospitals have admitted thousands of patients. The most common admitting diagnosis has been acute decompensated HF, and a rare combination of improving outcomes (reductions in readmissions, improved patient satisfaction, and reducing costs) has many pushing for this program to become permanent.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Describe the process and experiences of the Hospital-at-home care model caring for patients with ADHF.
- Discuss the CMS waiver experience with the Hospital-at-home care model.
- Discuss the logistics and delivery of the Hospital-at-home care model including medication administration, real-time monitoring, and reimbursement.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Kismet Rasmusson. Intermountain Healthcare, Salt Lake City, UT

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Celeste Williams. Henry Ford Health System, West Bloomfield, MI

Sunday, October 2 11:00AM - 11:10AM.

Acute Hospital Care at Home: The CMS Waiver Experience

Linda DeCherrie.¹

Discuss the history and current implications of the U.S. Centers for Medicare & Medicaid Services (CMS) Acute Hospital Care at Home (AHCaH) initiative, which allowed Medicare-certified hospitals to treat patients with inpatient-level care at home. Give brief overview of what this program looks like in terms of remote monitoring and remote patient-provider interactions.

Sunday, October 2 11:10AM - 11:20AM.

Wearable Technology in Hospital at Home

Eiran Gorodeski. University Hospitals, Cleveland, OH

Sunday, October 2 11:20AM - 11:30AM.

Mastering Meds: Pharmacy Needs for Hospital-at-home

Maggie Peinovich. Medically Home, Boston, MA

Discuss the logistics and needs to deliver intensive medical therapy for ADHF in hospital-at-home model with emphasis on common therapies in ADHF

Sunday, October 2 11:30AM - 11:40AM.

Financial models and value propositions of Hospital at Home

Michael Maniaci. Mayo Clinic, Jacksonville, FL

Discuss the financial models and value of hospital at home to institutions starting this program

Sunday, October 2 11:40AM - 11:50AM.

Hospital at home: There is no place like home

Michael Nassif. Saint Luke's Health System Kansas City

Compare and contrast with other models - traditional hospitalization, ambulatory infusion clinics, etc

Sunday, October 2 11:50AM - 12:00PM.

Audience Q&A / Panel Discussion

Session 18 - Myocardial Recovery: Patients with Improved and Dynamic EF

SESSION DETAILS

Session Title: Myocardial Recovery: Patients with Improved and Dynamic EF

Session Number: Session 18

Session Time: Sunday Oct 2, 2022 11:00 AM - 12:00 PM

Session Locations: National Harbor 10/11

Session Description: The proposed Session will address the definition, epidemiology, clinical predictors, and outcomes of patients with heart failure with improved ejection fraction. It will discuss the mechanisms of myocardial recovery including molecular and cellular changes that contribute to phenotypic changes in the size, shape, and function of the heart. The Session will address the clinical aspects of management of patients with improved/recovered ejection fraction such as can heart failure medications be stopped in these patients, how should these patients be followed up, and is implantable cardioverter-defibrillator generator replacement indicated in these patients. As many patients with stress-induced cardiomyopathy achieve a sustainable myocardial recovery, an update on pathophysiology and management of this condition will also be provided at the Session.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Define heart failure with improved ejection fraction.
- Discuss mechanisms of myocardial recovery.

- Evaluate the clinical management of patients with improved/recovered ejection fraction.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Kenneth Margulies. The University of Pennsylvania Health System, Villanova, PA

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Karol Harshaw-Ellis. VCU Health, Richmond, VA

Sunday, October 2 11:00AM - 11:13AM.

Heart failure with improved ejection fraction: definition, clinical predictors, and outcomes

Viorel Florea. Minneapolis Veterans Affairs Health Care System

This presentation will provide an overview of heart failure with improved ejection fraction, including explanation, epidemiology, demographics, and association with prognosis.

Sunday, October 2 11:13AM - 11:26AM.

Physiology of Myocardial Recovery

Douglas Mann. Washington University School of Medicine in St. Louis

Why are these patients still symptomatic? This presentation will explore the science behind myocardial recovery, including proposed mechanisms for recovery, itself, and for ongoing challenges surrounding treatment of heart failure symptoms in this population.

Sunday, October 2 11:26AM - 11:39AM.

Management of patients with improved EF

Jane Wilcox. Northwestern Memorial Hospital

Explores current evidence supporting clinical decision-making on continued treatment with guideline-directed medical therapies, after recovery.

Sunday, October 2 11:39AM - 11:52AM.

Stress-induced cardiomyopathy: Update on pathophysiology and management

Janet Wei. Cedar Sinai, Los Angeles, CA

Discusses cause of cardiomyopathy with high rates of expected recovery, to compare and contrast the mechanisms/pathways of recovery.

Sunday, October 2 11:52AM - 12:00PM.

Audience Q&A / Panel Discussion

Session 19 - Let's Talk About Sex (Differences in Heart Failure)

SESSION DETAILS

Session Title: Let's Talk About Sex (Differences in Heart Failure)

Session Number: Session 19

Session Time: Sunday Oct 2, 2022 11:00 AM - 12:00 PM

Session Locations: National Harbor 4/5

Session Description: HF continues to be a major contributor to morbidity & mortality for men and women alike, yet how the predisposition, course and mgt. of HF differs between men and women remains understudied. Sex differences in traditional risk factors as well as sex-specific risk factors influence the prevalence and manifestations of HF in unique ways among men and women, with implications for diagnosis and mgt. These factors then in turn contribute to sex specific variation in response to both pharmacologic and device/surgery therapy.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Identify factors that influence the course and management of HF between men and women.
- Describe sex-specific risk factors involved in the management of HF. Discuss sex differences in the management of HFpEF.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Eileen Hsieh. Cleveland Clinic Main Campus

Sunday, October 2 11:00AM - 11:00AM.

Moderator

Douglas Stoller. Nebraska Medicine Bellevue Health Center

Sunday, October 2 11:00AM - 11:10AM.

HFpEF - A disease more common in women, but why?

Harriette Van Spall.¹

HFpEF is more common in women as compared to men. Here we discuss known data as well as gaps in knowledge as to why HFpEF is more common in women

Sunday, October 2 11:10AM - 11:20AM.

Too far gone or missed opportunities? Cardiogenic Shock in women and rescue: a surgeon's perspective

Michael Tong. Cleveland Clinic

Women present with more severe cardiogenic shock than men and may need sex specific approaches to management of cardiogenic shock

Sunday, October 2 11:20AM - 11:30AM.

LVAD Therapy and Heart Transplantation in Women - Same Playing Field?

Bhavadarini Ramu. Medical University of South Carolina Health

Advanced HF therapies are underutilized in women. This presentation will review data from contemporary LVAD and heart transplantation studies.

Sunday, October 2 11:30AM - 11:40AM.

It's not the years of life, but the life in the years - Patient Centered Outcomes in Women

Gregory Lewis. Massachusetts General Hospital

This presentation will cover differences in exercise capacity and a focus on frailty and exercise hemodynamics in women as compared with men.

Sunday, October 2 11:40AM - 11:50AM.

Is now the time for sex specific guidelines in heart failure

Martha Gulati. Cedar Sinai, Los Angeles, CA

Sunday, October 2 11:50AM - 12:00PM.

Audience Q&A / Panel Discussion

Session 20 - Referral for Advanced HF Care

SESSION DETAILS

Session Title: Referral for Advanced HF Care

Session Number: Session 20

Session Time: Sunday Oct 2, 2022 2:15 PM - 3:45 PM

Session Locations: Potomac C

Session Description: Referrals for subspecialty care in cardiology, like advanced heart failure care, can be extremely complicated, and there are multiple potential barriers to referral for both patients and medical practitioners. Timely patient referral is critical to a good outcome and can enhance patient experiences and overall benefit of advanced therapies for heart failure. Furthermore, even if advanced heart failure therapies may not be an option for patients, advanced heart failure centers can provide additional resources, including multidisciplinary care, palliative care, social work, etc. The optimal or golden window for referral for an evaluation for advanced HF therapies (i.e., heart transplantation/left ventricular assist device) is when the severity of illness is consistent with advanced heart failure, but irreversible end-organ damage has not yet occurred, and the patient is not in extremis. To improve the referral process and provide high value care, the cardiovascular community needs a more nuanced approach to referral that optimizes the process for stakeholders. There are significant gaps in the understanding of factors that prevent timely referral for patients with worsening heart failure.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Provide timely referral for advanced heart failure.
- Discuss general cardiology perspective for referring patients.
- Describe the spectrum of services offered at an advanced HF center.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Mandeep Mehra. Mass General Brigham, Boston, MA

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Stuart Russell. Duke University Health, Raleigh, NC

Sunday, October 2 2:15PM - 2:30PM.

The General Cardiology Perspective: Why We Can't Refer Everyone with Heart Failure

Sunil Rao. Ascension Health, Grand Blanc Township, MI

Sunday, October 2 2:30PM - 2:45PM.

Advanced Heart Failure Trained Cardiologists in the Community: Our Role in Management and Referral

Kristen Maurice. Munson Hospital, Traverse City, MI

Sunday, October 2 2:45PM - 3:00PM.

Timely Referral for Advanced HF: What We Know and What We Don't Know

Prateeti Khazanie. The University of Colorado Health, Aurora, CO

Sunday, October 2 3:00PM - 3:15PM.

The Evolving Role of LVAD Only Centers in Providing Advanced HF Care

Sima Hodavance. Lehigh Valley Health Network, Allentown, PA

Sunday, October 2 3:15PM - 3:30PM.

Referral to an Advanced HF Center: The Patient Experience

Alex Sentayhu. Patient, Washington, DC

Sunday, October 2 3:30PM - 3:45PM.

Audience Q&A / Panel Discussion

Session 21 - Leveraging Genetics for Heart Failure Therapy: Where Are We Headed?

SESSION DETAILS

Session Title: Leveraging Genetics for Heart Failure Therapy: Where Are We Headed?

Session Number: Session 21

Session Time: Sunday Oct 2, 2022 2:15 PM - 3:45 PM

Session Locations: National Harbor 2/3

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Highlight early efforts at viral gene transfer for HF.
- Discuss applications of gene editing approaches for heart failure.

- Review gene silencing applications in heart failure Discuss role of CHIP in HF pathophysiology and potential implications for treatment.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Douglas Mann. Washington University School of Medicine in St. Louis

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Priya Umapathi. Johns Hopkins University School of Medicine

Sunday, October 2 2:15PM - 2:33PM.

Gene Therapy/Viral Gene Transfer for Heart Failure

Arthur Feldman. Renovacor, Inc.

Sunday, October 2 2:33PM - 2:51PM.

Gene Silencing to treat Heart Failure

Daniel Judge. Medical University of South Carolina Health

Sunday, October 2 2:51PM - 3:09PM.

Genome Editing approaches for Heart Failure

Pradeep Mammen. The University of Texas Southwestern Medical Center

Sunday, October 2 3:09PM - 3:27PM.

Clonal Hemaopoiesis of Indeterminate Potential: Implications for Heart Failure

Kenneth Walsh. Boston University

Sunday, October 2 3:27PM - 3:45PM.

Audience Q&A / Panel Discussion

Session 22 - Controversies in HFpEF

SESSION DETAILS

Session Title: Controversies in HFpEF

Session Number: Session 22

Session Time: Sunday Oct 2, 2022 2:15 PM - 3:45 PM

Session Locations: National Harbor 10/11

Session Description: While there have been incredible advances in the care in patients with heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF) continues to be a clinical challenge. The diagnosis and management of this syndrome can be frustrating for both clinicians and patients. While our understanding of the pathophysiology of HFpEF has increased, this has not yet translated into many successful therapeutic interventions. Clinical trial results have been underwhelming and continue to include patients with heart failure with mid-range ejection fraction (LVEF 40-49%), perhaps obscuring the results and their interpretation. The purpose of this session is the understand the current HFpEF landscape, particularly as it relates to heart failure treatment guidelines, novel therapeutic strategies, and trial design. This session will be a total of 90 minutes. Three debates will be held, with each presenter allotted 8 minutes to discuss his/her position. An additional 2 minutes will be given to each presenter at the end of the presentations for rebuttals and questions.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Discuss GDMT in HFpEF including the limitations of current data and the incorporation of medical therapy into the recent heart failure guidelines.
- Discuss pros and cons of ambulatory monitoring in HFpEF, including recent trials and the FDA decision to expand the indication for these devices.
- Describe the pros and cons of clinical trials enrollment by phenogroup.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Marvin Konstam. Tufts Medical Center, Boston, MA

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Katherine DiPalo. Albert Einstein College of Medicine, Bronx, NY

Sunday, October 2 2:15PM - 2:25PM.

Are there pillars of GDMT in HFpEF? PRO

Barry Borlaug. Mayo Clinic - Minnesota

HF guidelines in 2022 included therapeutic considerations for SGLT2i, MRAs, and ARNIs in

HFpEF patients for the reduction of cardiovascular endpoints. However, clinical trial data supporting these recommendations has sometimes been controversial, and clinical trials to date have mainly demonstrated reductions in heart failure hospitalizations as opposed to cardiovascular mortality. In this debate, the pro's and con's of the heart failure guideline recommendations will be discussed.

Sunday, October 2 2:25PM - 2:35PM.

Are there pillars of GDMT in HFpEF? CON

Lynne Stevenson. Vanderbilt University Health, Nashville, TN

HF guidelines in 2022 included therapeutic considerations for SGLT2i, MRAs, and ARNIs in HFpEF patients for the reduction of cardiovascular endpoints. However, clinical trial data supporting these recommendations has sometimes been controversial, and clinical trials to date have mainly demonstrated reductions in heart failure hospitalizations as opposed to cardiovascular mortality. In this debate, the pro's and con's of the heart failure guideline recommendations will be discussed.

Sunday, October 2 2:35PM - 2:45PM.

Does the evidence support ambulatory monitoring in HFpEF? PRO

JoAnn Lindenfeld. Vanderbilt University Health, Nashville, TN

Ambulatory monitoring using an implanted pulmonary artery device has the potential to reduce cardiovascular events in heart failure patients. While earlier studies suggested a benefit across the ejection fraction spectrum, more recent data are more controversial. Debaters will discuss these controversies, the recent FDA expanded indication for these devices, and when these devices should be considered in a given patient. Note: 8 minutes/presenter with an additional 4 minutes (2 min/presenter) for rebuttals and questions

Sunday, October 2 2:45PM - 2:55PM.

Does the evidence support ambulatory monitoring in HFpEF? CON

Larry Allen. The University of Colorado Health

Ambulatory monitoring using an implanted pulmonary artery device has the potential to reduce cardiovascular events in heart failure patients. While earlier studies suggested a benefit across the ejection fraction spectrum, more recent data are more controversial. Debaters will discuss these controversies, the recent FDA expanded indication for these devices, and when these devices should be considered in a given patient. Note: 8 minutes/presenter with an additional 4 minutes (2 min/presenter) for rebuttals and questions

Sunday, October 2 2:55PM - 3:05PM.

Rethinking Clinical Trial Design – Phenogroups vs. Global inclusion criteria (PRO GLOBAL)

Javed Butler. Baylor Scott & White Health, Atlanta, GA

The last debate will center on our current design and recruitment of subjects for clinical trials in HFpEF. This debate will focus on the relative merits of more inclusive trial design, as seen in PARAGON and EMPEROR Preserved, versus trials that seek to enroll specific 'phenogroups', such as in REDUCE-LAP or HELP trial of HFpEF with pulmonary hypertension. The pro stance will discuss the advantages of using more globally representative inclusion criteria, but also focus on how these can be improved, highlighting differences across major HFpEF trials. The contrary view will discuss the importance of using phenomapping to study specific HFpEF sub-populations using a more targeted approach. Note: 8 minutes/presenter with an additional 4 minutes (2 min/presenter) for rebuttals and questions

Sunday, October 2 3:05PM - 3:15PM.

Rethinking Clinical Trial Design – Phenogroups vs. Global inclusion criteria PRO PHENOGROUP

Sanjiv Shah. Northwestern University Feinberg School of Medicine, Chicago, IL

The last debate will center on our current design and recruitment of subjects for clinical trials in HFpEF. This debate will focus on the relative merits of more inclusive trial design, as seen in PARAGON and EMPEROR Preserved, versus trials that seek to enroll specific 'phenogroups', such as in REDUCE-LAP or HELP trial of HFpEF with pulmonary hypertension. The pro stance will discuss the advantages of using more globally representative inclusion criteria, but also focus on how these can be improved, highlighting differences across major HFpEF trials. The contrary view will discuss the importance of using phenomapping to study specific HFpEF sub-populations using a more targeted approach. Length: 8 minutes/presenter with an additional 4 minutes (2 min/presenter) for rebuttals and questions

Sunday, October 2 3:15PM - 3:30PM.

Wrap-Up: HFpEF - Where are we now?

Parag Goyal. Weill Cornell Medicine

This session ends with a wrap up lecture on the current state of HFpEF and summary of the debates key points.

Sunday, October 2 3:30PM - 3:45PM.

Audience Q&A / Panel Discussion

Session 23 - Global Innovations in the Care of Patients with Heart Failure

SESSION DETAILS

Session Title: Global Innovations in the Care of Patients with Heart Failure

Session Number: Session 23

Session Time: Sunday Oct 2, 2022 2:15 PM - 3:45 PM

Session Locations: National Harbor 4/5

Session Description: The session includes the annual Gheorghide Lecture, presentation of the 2022 International Honorary Fellows Awards and a roundtable of international heart failure society leaders on the topic innovations in advanced heart failure in their country or region.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 2:15PM - 2:20PM.

Introductory Comments

Mark Drazner. The University of Texas Southwestern Medical Center, Dallas, TX

Sunday, October 2 2:20PM - 2:45PM.

Gheorghide Lecture: *Heart Failure in Peripartum Women*

Karen Sliwa. The Cape Heart Institute, Cape Town, South Africa

Sunday, October 2 2:45PM - 2:55PM.

Presentation of the International Honorary Fellows Awards - Presented by Dr. Mark Drazner

Sunday, October 2 2:55PM - 2:55PM.

International Honorary Fellows Awardee

John Cleland. The University of Glasgow Institute of Health and Wellbeing, Glasgow, United Kingdom

Sunday, October 2 2:55PM - 2:55PM.

International Honorary Fellows Awardee

Anna Stromberg. Linkoping University, Linkoping, Sweden

Sunday, October 2 2:55PM - 2:55PM.

International Honorary Fellows Awardee

Faiez Zannad. ChU Brabois, France

Sunday, October 2 2:55PM - 3:45PM.

Roundtable: *Global Innovations in the Care of Patients with Heart Failure*

Amanda Vest. Tufts Medical Center, Boston, MA

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Anique Ducharme. Université de Montréal Faculty of Medicine, Westmount, QC, Canada

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Giuseppe Rosano. St. George's Hospitals NHS Trust University of London, London, United Kingdom

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Uday Jadhav.¹

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Bagirath Raghuraman. Narayana Institute of Cardiac Sciences, Bommasandra, Bangalore, India

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Yuya Matsue. Jutendo University Hospital, Tokyo, Japan

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Seok-Min Kang. Yonei University College of Medicine, Seodaemun-Gu, Korea, Republic of

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Sung-Hee Shin. Inha University Hospital (South Korea), Incheon, Korea, Republic of

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Juan Esteban Juan Esteban Gomez-Mesa. Cali, Colombia

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Feras Bader. Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Yosef Manla. Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Panel

Lisa Anderson. St. George's University Hospital of London, London, United Kingdom

Sunday, October 2 2:55PM - 3:45PM.

Roundtable Speaker

Lynn Mackay-Thomas. British Society for Heart Failure, London, United Kingdom

Session 24 - A Case-based Approach to Diagnosis and Management of Cardiac Amyloidosis

SESSION DETAILS

Session Title: A Case-based Approach to Diagnosis and Management of Cardiac Amyloidosis

Session Number: Session 24

Session Time: Sunday Oct 2, 2022 4:00 PM - 5:15 PM

Session Locations: Potomac C

Session Description: This session highlights recent advances in the diagnosis and management of light chain and transthyretin amyloidosis. It includes five presentations. Each speaker will have 12 minutes to present followed by 15 minutes for Q & A at the end of the session. Each presentation will include a briefcase.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Differentiate the epidemiology of and screening for light chain and transthyretin amyloidosis.

- Discuss staging, therapies, & multidisciplinary management of amyloidosis.
- Describe diagnostic modalities and new and emerging therapies for transthyretin amyloidosis.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Akshay Desai. Mass General Brigham

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Jo Ellen Rodgers. The University of North Carolina at Chapel Hill

Sunday, October 2 4:00PM - 4:12PM.

Epidemiology and Screening for Cardiac Amyloidosis: Who? How? When?

Brian Jensen. University of North Carolina at Chapel Hill, Chapel Hill, NC

Differentiate epidemiology and screening of light chain and transthyretin amyloidosis. A brief case should be included to apply content addressed.

Sunday, October 2 4:12PM - 4:24PM.

Staging and Therapies for Light Chain Amyloidosis: What a Cardiologist Needs to Know

Mathew Maurer. Columbia University Irving Medical Center

Discuss staging and disease modifying therapies for light chain amyloidosis. A brief case should be included to apply content addressed.

Sunday, October 2 4:24PM - 4:36PM.

A Quest for Accurate Diagnostic Modalities for Transthyretin Amyloidosis

Omar Abou Ezzeddine. Mayo Clinic, Rochester, MN

Review diagnostic modalities for transthyretin amyloidosis. A brief case should be included to apply content addressed.

Sunday, October 2 4:36PM - 4:48PM.

New and Emerging Therapies for Cardiomyopathy Associated with Transthyretin Amyloidosis

Amrut Ambardekar. The University of Colorado Health, Aurora, CO

Describe new and emerging therapies for transthyretin amyloidosis. A brief case should be included to apply content addressed.

Sunday, October 2 4:48PM - 5:00PM.

A Multidisciplinary Approach to the Management of Amyloidosis

Johana Fajardo. MedStar Health

Discuss the financial burden associated with management of transthyretin amyloidosis. A brief case should be included to apply content addressed.

Sunday, October 2 5:00PM - 5:15PM.

Audience Q&A / Panel Discussion

Session 25 - Inherited Dilated Cardiomyopathies: Can We Rewrite the Stars?

SESSION DETAILS

Session Title: Inherited Dilated Cardiomyopathies: Can We Rewrite the Stars?

Session Number: Session 25

Session Time: Sunday Oct 2, 2022 4:00 PM - 5:15 PM

Session Locations: Potomac D

Session Description:

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Highlight new insights regarding DCM genetics.
- Discuss evolving insights into risk stratification and management of specific DCM phenotypes.
- Provide practical guidance for clinicians regarding genetic testing in DCM and other inherited cardiomyopathies.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Douglas Stoller. Nebraska Medicine Bellevue Health Center

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Anjali Owens. Perelman School of Medicine at the University of Pennsylvania, Wallingford, PA

Sunday, October 2 4:00PM - 4:15PM.

DCM Genetics: New Insights from Epidemiology

Ray Hershberger. The Ohio State University Wexner Medical Center

--Highlight New Insights from Dilated Cardiomyopathy Precision Medicine Study. Discuss the impact of race and ethnicity on genetic testing.

Sunday, October 2 4:15PM - 4:30PM.

Taming the beast: Advances TTN Cardiomyopathy

J. Travis Hinson. Jackson Laboratory for Genomic Medicine

--Highlight science supporting role of TTN mutations in development of DCM --Showcase new insights from preclinical/translational data regarding contribution of TTN mutations in other cardiomyopathies (PPCM, ETOH, etc)--Highlight evolving approaches to leveraging genetics for specific treatment of DCM (focus on lamin)

Sunday, October 2 4:30PM - 4:45PM.

Lamin Cardiomyopathy: Towards Precision Medicine?

Neal Lakdawala. Mass General Brigham

-Highlight emerging approaches to targeted therapy

Sunday, October 2 4:45PM - 5:00PM.

Arrhythmogenic Cardiomyopathies: More Common Than You Think?

Adam Helms. University of Michigan

--DSP cardiomyopathy/ ARVC --approach to LV noncompaction and arrhythmia risk --role of cardiac MRI in assessment of VT risk --do all NICM patients with EF<35 warrant primary prevention ICD

Sunday, October 2 5:00PM - 5:15PM.

Genetic testing in DCM: Practical Guidance for Clinicians

Elizabeth Jordan. The Ohio State University College of Medicine, Columbus, OH

-- Patient selection for genetic testing -- Current genetic tests, interpretation of results -- Importance of genetic counseling -- Implementing family/cascade screening

Session 26 - 'Oh the place we'll need to go': Unmet needs and debates in cardiogenic shock

SESSION DETAILS

Session Title: 'Oh the place we'll need to go': Unmet needs and debates in cardiogenic shock

Session Number: Session 26

Session Time: Sunday Oct 2, 2022 4:00 PM - 5:15 PM

Session Locations: National Harbor 2/3

Session Description: Despite intense interest, the mortality of cardiogenic shock is little changed despite pharmaceutical and mechanical circulatory support options which continue to evolve. This session will highlight some of the key unmet needs in the field including the challenges of delineating optimal mechanical and pharmacologic shock therapies, debate the necessity of a shock team and discuss how to best address these unmet needs.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Describe unmet needs in delineating optimal mechanical and pharmacologic therapies for cardiogenic shock.
- Discuss optimal approaches to closing the clinical gaps in cardiogenic shock. Explain the utility and roles of cardiogenic shock team.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Stavros Drakos. The University of Utah Health, Salt Lake City, UT

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Carolyn Rosner. Inova Health System

Sunday, October 2 4:00PM - 4:10PM.

Cardiogenic Shock & Other Organs: Optimal RRT and cardioprotective ventilation strategies

Jason Katz. Duke University School of Medicine

Presenter will review management of non-cardiac organ dysfunction in the setting of cardiogenic shock.

Sunday, October 2 4:10PM - 4:20PM.

The Endgame: Weaning Algorithms and Exit Strategies in Cardiogenic Shock

Jennifer Cowger. Henry Ford Health System

Presenter will discuss unmet needs in delineating how to optimally wean mechanical circulatory support and bridge to the exit strategy.

Sunday, October 2 4:20PM - 4:30PM.

DEBATE: Shock team: necessity not luxury

Behnam Tehrani. INOVA

The presenter should discuss the reasons and evidence supporting the viewpoint that a dedicated shock team is a necessity for hospitals. This will be followed by a counterpoint.

Sunday, October 2 4:30PM - 4:40PM.

DEBATE: Shock team: luxury not necessity

Manreet Kanwar. Allegheny Health Network, Pittsburgh, PA

The presenter should discuss the reasons and evidence supporting the viewpoint that a dedicated shock team is NOT a necessity for hospitals. This will be preceded by the counterpoint.

Sunday, October 2 4:40PM - 4:50PM.

DEBATE: How to move to ball in the Science of shock? Real world experience rather than RCT

Ali Nsair. University of California, Los Angeles, Los Angeles, CA

Sunday, October 2 4:50PM - 5:00PM.

DEBATE: How to move to ball in the Science of shock? RCT rather than real world experience

Filio Billia. University of Toronto, Toronto, ON, Canada

The presenter should discuss the reasons and evidence supporting the viewpoint that the best method to advance scientific evidence for the care of shock are randomized controlled trials. This will be preceded by a counterpoint.

Sunday, October 2 5:00PM - 5:15PM.

Audience Q&A / Panel Discussion

Session 27 - Implications of Comorbidities Across the HF Continuum

SESSION DETAILS

Session Title: Implications of Comorbidities Across the HF Continuum

Session Number: Session 27

Session Time: Sunday Oct 2, 2022 4:00 PM - 5:15 PM

Session Locations: National Harbor 10/11

Session Description: Describes common comorbidities across the ejection fraction spectrum in heart failure and their implications and discusses treatment decisions related to comorbidities.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Describe the incidence and implications of several major comorbidities across the ejection fraction spectrum.
- Compare and contrast differences in the incidence and significance of these comorbid conditions between HFpEF and HFrEF.
- Discuss treatment options for comorbid conditions.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Teri Diederich. Nebraska Medicine Bellevue Health Center

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Timothy Fendler. Saint Luke's Health System Kansas City, Kansas City, MO

Sleep Disordered Breathing in HF

Lisa Bratzke. University of Wisconsin

This presentation will discuss the screening, diagnosis, incidence, and implications of obstructive sleep apnea, central sleep apnea, and Cheyne-Stokes respiration in adults with heart failure. Special attention to trial data and treatment modalities, along with observed outcomes, will be made.

Sunday, October 2 4:10PM - 4:20PM.

HF and the Kidneys - Far reaching Implications

Jeffrey M. Testani. Yale University, New Haven, CT

Despite demonstrated cardiac abnormalities, congestion also requires complicit actions of the kidney to retain salt and water. This talk will discuss the implications of renal dysfunction in the context of HFpEF and HFrEF and strategies known to preserve renal function in these conditions.

Sunday, October 2 4:20PM - 4:30PM.

Cardiac Metabolism Along the HF Continuum

Senthil Selvaraj. The University of Pennsylvania Health System, Durham, NC

Alterations in cardiac fatty acid and glucose metabolism occur in HFrEF, with different derangements present depending on the severity of heart failure. Less is known about cardiac metabolism in HFpEF, though burgeoning data suggest abnormalities in both myocardial and skeletal muscle oxidative phosphorylation. This talk will review what is known about cardiac metabolism in each condition, drawing attention to the different techniques available to study

Sunday, October 2 4:30PM - 4:40PM.

Skeletal Muscle in HF: Mechanisms and implications

Stefan Anker.¹

Skeletal muscle abnormalities, including decreased muscle mass and quality, have far reaching implications in all forms of heart failure. This talk will discuss the mechanisms and implications of skeletal muscle abnormalities seen in both HFrEF and HFpEF. Treatment options will be reviewed.

Sunday, October 2 4:40PM - 4:50PM.

Iron Deficiency in HF

Stormi Gale. Novant Health

This talk will discuss the diagnostic criteria and implications of iron deficiency in heart failure (HFrEF and HFpEF). The consequence of impaired iron metabolism will be discussed, along with completed and ongoing studies evaluating the impact of iron repletion on functional and cardiovascular endpoints.

Sunday, October 2 4:50PM - 5:15PM.

Audience Q&A / Panel Discussion

Session 28 - Excellence in Translational Science

SESSION DETAILS

Session Title: Excellence in Translational Science

Session Number: Session 28

Session Time: Sunday Oct 2, 2022 4:00 PM - 5:30 PM

Session Locations: National Harbor 4/5

[FULL SESSION DETAILS](#) – *Speakers subject to change*

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Daniel Garry. The University of Minnesota Medical School, Minneapolis, MN

Sunday, October 2 4:00PM - 4:00PM.

Moderator

Cheryl Westlake. Azusa Pacific University, San Clemente, CA

Sunday, October 2 4:00PM - 4:20PM.

Tom Force Lecture: Pigs as a source for cardiac xeno-Transplantation

Eckhard Wolf. Gene Center, LMU Munich, Munich, Germany

Sunday, October 2 4:20PM - 4:40PM.

The potential of xenotransplantation in infants with complex congenital heart disease

David KC Cooper. Massachusetts General Hospital, Boston, MA

Sunday, October 2 4:40PM - 5:00PM.

Cardiac Xenotransplantation: Progress and challenges

Christopher McGregor. University of Minnesota, Minneapolis, MN

Sunday, October 2 5:00PM - 5:30PM.

Panel Discussion

Sunday, October 2 5:30PM - 5:30PM.

Panelist

Eckhard Wolf. Gene Center, LMU Munich, Munich, Germany

Sunday, October 2 5:30PM - 5:30PM.

Panelist

David KC Cooper. Massachusetts General Hospital, Boston, MA

Sunday, October 2 5:30PM - 5:30PM.

Panelist

Christopher McGregor. University of Minnesota, Minneapolis, MN

Sunday, October 2 5:30PM - 5:30PM.

Panelist

Muhammad Mohiuddin. University of Maryland, Baltimore, MD

Session 29 - Heart Failure Research Update: Conducting HF Trials in the U.S.

SESSION DETAILS

Session Title: Heart Failure Research Update: Conducting HF Trials in the U.S.

Session Number: Session 29

Session Time: Monday Oct 3, 2022 9:45 AM - 10:45 AM

Session Locations: Potomac C

Session Description: This session will provide an overview of the HFSA Research Network goals, objectives and progress.

Vision: Improve the health of HF patients through high value clinical research.

Mission:

1. To establish an integrated high quality, high value heart failure network of investigators committed to conducting clinical research in order to improve our understanding and care of the heart failure patients that we serve.
2. To improve the conduct of clinical research in North America and our international partners.
3. To contribute to the Educational Mission of the HFSA by enhancing the conduct of heart failure clinical research.
4. To educate heart failure patients regarding the value of participation in clinical research studies and develop novel methods to actively engage them in clinical research.
5. To add value to the Heart Failure Society of America's overall mission.

[FULL SESSION DETAILS](#) – *Speakers subject to change*

Monday, October 3 9:45AM - 9:45AM.

Moderator

Christopher O'Connor. Inova Health System

Monday, October 3 9:45AM - 9:50AM.

Opening Remarks: HFSA Research Network Accomplishments

Christopher O'Connor. Inova Health System

Monday, October 3 9:50AM - 10:00AM.

Review and challenges of current HF trials (Focus on RN trials)

John Teerlink. San Francisco Veterans Affairs Health Care System

Focus on Research Network Trials

Monday, October 3 10:00AM - 10:10AM.

Focus on Diversity - how to improve enrollment of underrepresented patients

Melvin Echols. Morehouse School of Medicine

Monday, October 3 10:10AM - 10:25AM.

HFC/HFSA Site Based Research Clinical Trial Awards and Recognition

Mona Fiuzat. Duke University School of Medicine

5 min each - Top PI, Top SC, Top Site (total 15 min) - (alternate award presenters - Chris O'Connor and Mona Fiuzat)

Monday, October 3 10:25AM - 10:45AM.

Help Shape the Future of Heart Failure Research in U.S: Open Discussion/Next Steps

Monday, October 3 10:25AM - 10:45AM.

Help Shape the Future of Heart Failure Research in U.S: Open Discussion/Next Steps - Panelist

Quin Denfeld. Oregon Health and Science University, Portland, OR

Monday, October 3 10:25AM - 10:45AM.

Help Shape the Future of Heart Failure Research in U.S: Open Discussion/Next Steps - Panelist

Larisa G. Tereshchenko. Oregon Health and Science University, Portland, OR

Monday, October 3 10:25AM - 10:45AM.

Help Shape the Future of Heart Failure Research in U.S: Open Discussion/Next Steps - Panelist

Katelyn Bruno. University of Florida, Gainesville, FL

Monday, October 3 10:25AM - 10:45AM.

Help Shape the Future of Heart Failure Research in U.S: Open Discussion/Next Steps - Panelist

Thomas Cascino. The University of Michigan Medical School - Michigan Medicine, Ann Arbor, MI

Session 30 - Signed, Sealed, and DELIVERed

SESSION DETAILS

Session Title: Signed, Sealed, and DELIVERed

Session Number: Session 30

Session Time: Monday Oct 3, 2022 9:45 AM - 11:00 AM

Session Locations: National Harbor 2/3

Session Description: Lectures and panel discussion on the emerging translational and clinical science related to the DELIVER trial and its recently reported results, implications for SGLT2i use in heart failure.

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 9:45AM - 9:45AM.

Moderator

Orly Vardeny. The University of Minnesota Medical School, Minneapolis, MN

Monday, October 3 9:45AM - 9:45AM.

Moderator

David Lanfear. Henry Ford Health System, Detroit, MI

Monday, October 3 9:45AM - 9:57AM.

Knowledge update: best science on SGLT2i mechanism of action in HF

Sanjiv Shah. Northwestern University Feinberg School of Medicine, Chicago, IL

Monday, October 3 9:57AM - 10:09AM.

Design and Baseline characteristics in DELIVER: comparisons with other HFpEF trials

John McMurray. Cardiovascular Research Centre

Monday, October 3 10:09AM - 10:21AM.

Effects of dapagliflozin on clinical outcomes in the DELIVER Trial and comparison to other SGLT2i

Scott Solomon. Mass General Brigham

Monday, October 3 10:21AM - 10:33AM.

Independent commentary on DELIVER (unanswered questions? class effect?)

Nancy Sweitzer. Washington University in St. Louis, St. Louis, MO

Monday, October 3 10:33AM - 10:45AM.

Are SGLT2 inhibitors the new standard of care in HFpEF?: summary of clinical trial data and comparison to impact in HFrEF

Kavita Sharma. Johns Hopkins University, Baltimore, MD

Monday, October 3 10:45AM - 11:00AM.

Audience Q&A / Panel Discussion

Session 31 - Emerging Concepts in Myocarditis – Immunity, Infection, Immunization

SESSION DETAILS

Session Title: Emerging Concepts in Myocarditis – Immunity, Infection, Immunization

Session Number: Session 31

Session Time: Monday Oct 3, 2022 9:45 AM - 10:45 AM

Session Locations: National Harbor 10/11

Session Description: 60-Minute Session This session will focus on the diagnosis and management of inflammatory heart disorders, highlighting advances in multi-modality imaging to guide management of these disorders. Talks will emphasize emerging concepts in sarcoidosis, vaccine-associated myocarditis, and immune-checkpoint inhibitor-related myocarditis. Each speaker is encouraged to present the assigned topic in the context of a relevant clinical case.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Highlight emerging approaches to diagnosis and management of cardiac sarcoidosis. Discuss the prevalence and therapeutic implications of vaccine-associated myocarditis.
- Review the diagnosis and management of immune-checkpoint inhibitor-related myocarditis.

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 9:45AM - 9:45AM.

Moderator

Leslie Cooper. Mayo Clinic - Florida

Monday, October 3 9:45AM - 9:45AM.

Moderator

Theodore Berei. The University of Wisconsin Health

Monday, October 3 9:45AM - 10:00AM.

Cardiac Sarcoidosis: Leveraging Multi-modality Imaging for Inflammatory Heart Disease

Sanjay Divakaran. Brigham and Women's Hospital

Review emerging concepts in evaluation and management of cardiac sarcoidosis, emphasizing integration of multi-modality imaging.

Monday, October 3 10:00AM - 10:15AM.

Cardiac Sarcoidosis: Developing a Therapeutic Strategy

Nisha Gilotra. Johns Hopkins University School of Medicine

Monday, October 3 10:15AM - 10:30AM.

Myocarditis in the COVID-19 Era: The Vaccines vs. The Virus

Margaret Ryan. University of California, San Diego

Discuss emerging evidence regarding contribution of vaccines to risk of myocarditis. Ideally, the speaker would place this risk in the context of myocarditis and other CV complications related to COVID-infection to highlight the balance of risk and benefit.

Monday, October 3 10:30AM - 10:45AM.

Myocarditis Related to Immune Checkpoint Inhibitors: Recognition and Management

Anju Nohria. Mass General Brigham

Session 32 - Debating Volume-based Versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure

SESSION DETAILS

Session Title: Debating Volume-based Versus Pressure-based Methods and Devices to Measure Congestion in Heart Failure

Session Number: Session 32

Session Time: Monday Oct 3, 2022 9:45 AM - 10:45 AM

Session Locations: National Harbor 4/5

Session Description: In a debate format, we will compare pressure-based versus volume-based measures of congestion. The superiority of pressure versus volume measures will be discussed from the perspective of physiology, pathophysiology, and novel devices and diagnostic methods to assess congestion in ADHF.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Compare and contrast pressure versus volume-based metrics of congestion in HF.
- Describe the discrepancies between volume and pressure in quantifying congestion in HF.
- Outline the advances and limitations of novel devices and procedures to measure congestion in HF.

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 9:45AM - 9:45AM.

Moderator

Maria Rosa Costanzo. Edward-Elmhurst Health

Monday, October 3 9:45AM - 9:45AM.

Moderator

Marat Fudim. Durham, NC

Monday, October 3 9:45AM - 9:55AM.

Physiologic Perspective: Congestion is best measured by Intravascular pressure-based metrics

Jennifer Thibodeau. The University of Texas Southwestern Medical Center

This session should focus on the physiology/ pathophysiologic reasons that congestion is best measured by pressure-based metrics. The subsequent talk will focus on advances in pressure-based devices and analyses to measure congestion.

Monday, October 3 9:55AM - 10:05AM.

Physiologic Perspective: Congestion is best measured by Volume-based metrics

Wayne Miller. Mayo Clinic - Minnesota

This session should focus on the physiology/ pathophysiologic reasons that congestion is best measured by volume-based metrics. The subsequent talk will focus on advances in pressure-based devices and analyses to measure congestion.

Monday, October 3 10:05AM - 10:15AM.

Recent advances in devices and techniques to measure congestion: Intravascular pressure-based diagnostics are superior

Tamas Alexy. The University of Minnesota Medical School, North Oaks, MN

Discuss novel devices and diagnostic procedures using pressure measures of congestion (CardioMEMs, Volumetrix NIVAHF, POCUS measurements, etc)

Monday, October 3 10:15AM - 10:25AM.

Recent advances in devices and techniques to measure congestion: Volume-based diagnostics are superior

Jeffrey Testani. Yale

Include novel devices and diagnostic procedures using volume measures of congestion (IVC measurements and IVC implantable devices, blood volume assessments, POCUS measurements, etc)

Monday, October 3 10:25AM - 10:45AM.

Audience Q&A / Panel Discussion

Session 33 - The Evolving Care of Patients with Durable LVADs in Advanced HF Care

SESSION DETAILS

Session Title: The Evolving Care of Patients with Durable LVADs in Advanced HF Care

Session Number: Session 33

Session Time: Monday Oct 3, 2022 11:00 AM - 12:00 PM

Session Locations: Potomac C

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 11:00AM - 11:00AM.

Moderator

Joyce Wald. The University of Pennsylvania Health System, Philadelphia, PA

Monday, October 3 11:00AM - 11:00AM.

Moderator

Mustafa Ahmed. The University of Florida Health, Gainesville, FL

Monday, October 3 11:00AM - 11:10AM.

Is There A Perfect Patient for Durable LVAD?

Parag Patel. Jacksonville, FL

Monday, October 3 11:10AM - 11:20AM.

Turned Down for What? The Psychosocial Evaluation and Standards for LVAD and Transplantation

Christopher Knoepke. Highlands Ranch, CO

Monday, October 3 11:20AM - 11:30AM.

It's Electrifying! Management of Ventricular Arrhythmias in Patients with LVADs

Sana Al-Khatib. Duke University, Durham, NC

Monday, October 3 11:30AM - 11:40AM.

N'Sync or Not N'Sync: The LV lead after LVAD implantation

Andrew Sauer. The University of Kansas Health System, Kansas City, KS

Monday, October 3 11:40AM - 11:50AM.

Right Heart, Right Now: Managing Right Heart Failure after LVAD implantation

Michael Kiernan. Tufts Medical Center, Wellesley, MA

Monday, October 3 11:50AM - 12:00PM.

Audience Q&A / Panel Discussion

Session 34 - Clinical Conundrums

SESSION DETAILS

Session Title: Clinical Conundrums

Session Number: Session 34

Session Time: Monday Oct 3, 2022 11:00 AM - 12:00 PM

Session Locations: Potomac D

Session Description: This session will utilize a case-based format to address challenging clinical situations for patients with heart failure in both the inpatient and outpatient setting. Each moderator will walk through an interactive case discussion that will allow panelists from multiple disciplines to discuss specific challenges related to the management of the respective cases.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Discuss current treatment challenges for patients with cardiogenic shock.
- Review monitoring modalities to identify clinical deterioration in patients with cardiogenic shock.
- Present treatment options to manage complications in patients with cardiogenic shock

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 11:00AM - 11:00AM.

Moderator

Steven P. Dunn.¹

Monday, October 3 11:00AM - 11:00AM.

Moderator

Esther Vorovich. Northwestern University Feinberg School of Medicine, Wilmette, IL

Monday, October 3 11:00AM - 11:00AM.

Panelist

Michael Givertz. Mass General Brigham, Boston, MA

Monday, October 3 11:00AM - 11:00AM.

Panelist

Carolyn Rosner. Inova Health System, Falls Church, VA

Monday, October 3 11:00AM - 11:00AM.

Panelist

Jenna Cox. Prisma Health, Columbia, SC

Monday, October 3 11:00AM - 11:25AM.

Case 1

Steven P. Dunn.¹

This case discussion will focus on a complex cardiogenic shock case initially managed with a percutaneous mechanical circulatory support (e.g., Impella). Case elements to consider that will engage each discipline represented on the panel include monitoring (e.g., bleeding, clinical status, pump performance, etc.), adverse reactions (e.g., HIT and MCS anticoagulation), pump failure/thrombosis & related monitoring/therapeutic considerations. The moderator/speaker will provide case details progressively, stopping to pose questions to the panel.

Monday, October 3 11:25AM - 11:50AM.

Case 2

Esther Vorovich. Northwestern University Feinberg School of Medicine, Wilmette, IL

This case discussion will focus on a strategies for initiating GDMT in challenging patients with symptomatic HFrEF. Points to consider are strategies for initiating “quadruple therapy”, in general, and tailoring this approach to complex patients (e.g., advanced CKD, low blood pressure, and/or renal transplant recipients). The moderator/speaker will provide case details progressively, stopping to pose questions to the panel.

Monday, October 3 11:50AM - 12:00PM.

Audience Q&A / Panel Discussion

Session 35 - Health Equity in Heart Failure: Provider and Patient Perspectives

SESSION DETAILS

Session Title: Health Equity in Heart Failure: Provider and Patient Perspectives

Session Number: Session 35

Session Time: Monday Oct 3, 2022 11:00 AM - 12:00 PM

Session Locations: National Harbor 10/11

Session Description: This multidisciplinary session will focus on the utilization of a 3-pronged approach to achieving health equity in heart failure. Through Science, Advocacy and Education we can begin the long journey to reaching true health equity in heart failure care delivery. This session will address the identification of disparities, define social determinants of health and strategies to improve outcomes. The value of these presentations and discussion include will expose the audience to current health disparities specific to heart failure, raise awareness of ongoing efforts and provide real life strategies for implementation within their organization. The multidisciplinary panel contains specific expertise to health equity specific to the heart failure population.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Identify the 3-pronged approach to achieving health equity in heart failure.
- Recognize key elements in achieving health equity in heart failure patients.
- Provide examples of health disparities specific to heart failure.

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 11:00AM - 11:00AM.

Moderator

Maghee Disch. The American College of Cardiology

Monday, October 3 11:00AM - 11:00AM.

Moderator

Zara Latif. Harvard

Monday, October 3 11:00AM - 11:10AM.

Are Women and Underrepresented Minority Physicians Treated and Compensated Equally as their Male/Non

Anju Bhardwaj. The University of Texas Health Science Center at Houston

We discuss the initiatives to ensure DEI strategies to recruit and retain talented women and URM in the field of heart failure.

Monday, October 3 11:10AM - 11:20AM.

Health Disparities: Perspective from the 2022 Heart Failure Guidelines

Shannon Dunlay. Mayo Clinic - Minnesota

Review the 2022 Guideline recommendations for addressing racial and ethnic health disparities in heart failure outcomes.

Monday, October 3 11:20AM - 11:30AM.

Advances in the Science and Education of Health Disparities

Sakima Smith. The Ohio State University Wexner Medical Center

Focus on implementation of guideline recommendations for addressing health disparities

Monday, October 3 11:30AM - 11:40AM.

Social Determinants of Health in Heart Failure

Khadijah Breathett. Indiana University School of Medicine, Indianapolis, IN

This talk will explore the impact of SDH on Management and Outcomes in Heart Failure

Monday, October 3 11:40AM - 11:50AM.

Understanding the Patient Experience of Disparities in Heart Failure

Leslie Davis. The University of North Carolina at Chapel Hill

This session will explore the role of qualitative research in understanding and characterizing patients' experiences while living with heart failure.

Monday, October 3 11:50AM - 12:00PM.

Audience Q&A / Panel Discussion

Session 36 - Great Debates

SESSION DETAILS

Session Title: Great Debates

Session Number: Session 36

Session Time: Monday Oct 3, 2022 11:00 AM - 12:00 PM

Session Locations: National Harbor 4/5

Session Description: This session will feature debates on 3 controversial topics in the treatment of patients with heart failure: the clinical utility of the ejection fraction, the role of mavacamten to treat hypertrophic cardiomyopathy, and whether cannabis use should be a contraindication for heart transplant.

Learning Objectives:

At the conclusion of this educational activity, the learner will be able to:

- Describe the pros and cons of using ejection fraction to guide treatment decisions in patients with heart failure.
- Discuss the role cannabis use has on heart transplant eligibility.
- Describe the clinical and economic impact of using mavacamten to treat hypertrophic cardiomyopathy.

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 11:00AM - 11:00AM.

Moderator

Robert DiDomenico. The University of Illinois at Chicago, Chicago, IL

Monday, October 3 11:00AM - 11:00AM.

Moderator

Cheryl Westlake. Azusa Pacific University, San Clemente, CA

Monday, October 3 11:00AM - 11:10AM.

PRO: With Entresto and SGLT2i approved regardless of EF, now is finally the time for EF to be ejected

Javed Butler. Baylor Scott & White Health, Atlanta, GA

Monday, October 3 11:10AM - 11:10AM.

CON: EF still, and always will, matter

Mary Walsh. Ascension Medical Group, Indianapolis, IN

Monday, October 3 11:20AM - 11:30AM.

PRO: (Free the weed): non-smoking cannabis is mainstream and not dangerous and thus should not be a contraindication for heart transplant

Robert Page. University of Colorado, Denver, CO

Monday, October 3 11:30AM - 11:40AM.

CON (up with hope, down with dope): cannabis abuse is still a problem (and a federal crime) and should be a contraindication for heart transplant

Larry Allen. The University of Colorado Health, Denver, CO

Monday, October 3 11:40AM - 11:50AM.

PRO (Progress is worth the price): mavacamten should be the preferred treatment for symptomatic patients with hypertrophic cardiomyopathy

Ahmad Masri. Oregon Health and Science University, Portland, OR

Monday, October 3 11:50AM - 12:00PM.

CON (Pricey and Dicey): mavacamten is more expensive and more risky than more proven treatments.

Martin Maron. Tufts University School of Medicine, Boston, MA

Session 37 - Late Breaking Clinical Trials II

SESSION DETAILS

Session Title: Late Breaking Clinical Trials II

Session Number: Session 37

Session Time: Sunday Oct 2, 2022 9:45 AM - 10:45 AM

Session Locations: Potomac C

Session Description: Late Breaking Clinical Trials is an always-popular session where speakers present the results of a new research in heart failure. Late Breaking Clinical Trials II

provides exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Gerasimos Filippatos. Athens, Greece

Sunday, October 2 9:45AM - 9:45AM.

Moderator

Mark Drazner. The University of Texas Southwestern Medical Center, Dallas, TX

Sunday, October 2 9:45AM - 9:55AM.

The Effects Of Istaroxime In Patients With Pre-cardiogenic Shock Due To Acute Heart Failure - Dose Response

Steven Simonson. Windtree Therapeutics, Inc., Kennett Square, PA

Sunday, October 2 9:55AM - 10:00AM.

Q&A / Discussion: SEISMIC

Sunday, October 2 10:00AM - 10:10AM.

Usefulness Of Left Atrial Appendage Exclusion During Left Ventricular Assist Device Implantation: An Outcomes Analysis From The Momentum 3 Randomized Clinical Trial

Akinobu Itoh. Brigham and Women's Hospital/Harvard Medical School, Boston, MA

Sunday, October 2 10:10AM - 10:15AM.

Q&A / Discussion: MOMENTUM 3

Sunday, October 2 10:15AM - 10:25AM.

Improvement In KCCQ Scores In Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Aficamten In The REDWOOD-HCM OLE Study

Sara Saberi. Ann Arbor, MI

Sunday, October 2 10:25AM - 10:30AM.

Q&A / Discussion: REDWOOD-HCM OLE

Sunday, October 2 10:30AM - 10:40AM.

GRAHF2: Genomic Response Analysis Of Heart Failure Therapy In African Americans

Dennis McNamara. The University of Pittsburgh Medical Center, Venetia, PA

Sunday, October 2 10:40AM - 10:45AM.

Q&A / Discussion: GRAHF2

Session 38 - Multidisciplinary Heart Failure Clinics

SESSION DETAILS

Session Title: Multidisciplinary Heart Failure Clinics

Session Number: Session 38

Session Time: Sunday Oct 2, 2022 2:15 PM - 3:15 PM

Session Locations: Potomac D

Session Description: Guideline-directed medical therapy (GDMT) is the cornerstone of care for heart failure patients. Despite this the CHAMP registry showed that a significant number of patients are not on optimal GDMT. The FDA approval of SGLT2-i has increased medications to optimize for HFrEF patients. Many single-center studies have described GDMT optimization clinics. This session will focus on these clinics and best ways to care for HFrEF patients.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Rebecca Reay. Cleveland Clinic, Cleveland, OH

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Stephanie Barnes. Duke University Hospital, Durham, NC

Sunday, October 2 2:15PM - 2:15PM.

Moderator

Karen Harkness. Toronto

Sunday, October 2 2:15PM - 2:27PM.

The Role of Pharmacists in GDMT Clinics

Courtney Shakowski. University of Colorado

This session will describe the role that pharmacists play in optimizing GDMT for patients and how to integrate them into clinics.

Sunday, October 2 2:27PM - 2:39PM.

The Role of Dieticians in GDMT Clinics

Salvatore Carbone. Virginia Commonwealth University

Highlight role of dietician in providing comprehensive care for heart failure patients; best practices integrating dietician in heart failure clinics.

Sunday, October 2 2:39PM - 2:51PM.

Optimizing GDMT in the USA

Teri Diederich (HFSA & AAHFN Committee member). Nebraska Medicine

Literature describes best practices for GDMT clinics for heart failure patients. Session will highlight successful clinic programs/designs in the USA.

Sunday, October 2 2:51PM - 3:03PM.

Optimizing GDMT in Canada

Rodolfo Pike (CHFS Nursing Committee Chair). Eastern Health

Literature describes best practices for GDMT clinics for heart failure patients. Session will highlight successful clinic programs/designs in Canada.

Sunday, October 2 3:03PM - 3:15PM.

Audience Q&A / Panel Discussion

Session 39 - Special DELIVERy: Emerging Insights related to the DELIVERED trial

SESSION DETAILS

Session Title: Special DELIVERy: Emerging Insights related to the DELIVERED trial

Session Number: Session 39

Session Time: Monday Oct 3, 2022 7:00AM - 7:45AM

Session Locations: National Harbor 2/3

FULL SESSION DETAILS – *Speakers subject to change*

Monday Oct 3, 2022 7:00AM - 7:00AM.

Moderator

TBD

Monday Oct 3, 2022 7:00AM - 7:00AM.

Moderator

Javed Butler. Jackson, MS

Monday Oct 3, 2022 7:00AM - 7:10AM.

Time To Clinical Benefit Of Dapagliflozin In Heart Failure With Mildly Reduced And Preserved Ejection Fraction In The Deliver Trial

Muthiah Vaduganathan. Brigham and Women's Hospital/Harvard Medical School, Cambridge, MA

Monday Oct 3, 2022 7:10AM - 7:20AM.

Effect Of Dapagliflozin On Mode Of Death In Patients With Heart Failure And Mildly Reduced Or Preserved Ejection Fraction Enrolled In The DELIVER Trial

Akshay Desai. Mass General Brigham, Boston, MA

Monday Oct 3, 2022 7:20AM - 7:30AM.

Translating The Findings Of The Deliver Trial To Medicare Beneficiaries Hospitalized For Hf In The Us

Muthiah Vaduganathan. Brigham and Women's Hospital/Harvard Medical School, Cambridge, MA

Monday Oct 3, 2022 7:30AM - 7:45AM.

Audience Q&A / Panel Discussion

Plenary 01 - Presidential Plenary Session

SESSION DETAILS

Session Title: Presidential Plenary Session

Session Number: Presidential Plenary Session

Session Time: Saturday Oct 1, 2022 9:30 AM - 11:30 AM

Session Locations: Potomac A/B

Session Description: Join us for this year's Presidential Plenary and our opening keynote address:

Creation and Translation: Making Discoveries and Bringing Them to the Bedside, Michael Bristow, MD, PhD, Professor of Medicine (Cardiology) at the University of Colorado Anschutz Medical Campus, and Director of the Section of Pharmacogenomics in the University of Colorado Cardiovascular Institute

Setting the Agenda: Funding Strategies to Maximize Innovation, Gary Gibbons, MD, Director of the National Heart, Lung, and Blood Institute (NHLBI)

Discussion: Drs Bristow and Gibbons will be joined by additional panelists in a discussion on how to enhance and sustain innovation in the field.

Also featured during the Opening Plenary session:

HFSA President's Address

- **Mark Drazner, MD, MSc, FHSA**, HFSA President
- **John Teerlink, MD**, HFSA President-Elect and Director of Heart Failure and of the Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center
- **HFSA Award announcements**

[FULL SESSION DETAILS](#) – *Speakers subject to change*

Saturday, October 1 9:30AM - 10:15AM.

Opening Remarks

John Barnes. HFSA CEO, Rockville, MD

Saturday, October 1 9:30AM - 10:15AM.

President's Address - Outgoing President Address

Mark Drazner. The University of Texas Southwestern Medical Center, Dallas, TX

Saturday, October 1 9:30AM - 10:15AM.

President's Address - Incoming President Address

John Teerlink. San Francisco Veterans Affairs Health Care System, San Francisco, CA

Saturday, October 1 9:30AM - 10:15AM.

Award Announcements

Saturday, October 1 9:30AM - 10:15AM.

Lifetime Achievement Awards Announcement + Awardee Acceptance Presentations

Saturday, October 1 10:15AM - 11:30AM.

Keynote Address: The Importance of Innovation in Heart Failure: Perspectives on the Science, Regulatory Impact, and Funding Initiatives (10:15 - 11:30 AM)

Saturday, October 1 10:15AM - 11:30AM.

Keynote Moderator

Biykem Bozkurt. Baylor College of Medicine, Houston, TX

Saturday, October 1 10:15AM - 11:30AM.

Keynote Moderator

Harriette Van Spall. ¹

Saturday, October 1 10:15AM - 10:40AM.

Creation and Translation: Making Discoveries and Bringing Them to the Bedside

Michael R. Bristow. The University of Colorado Health, Aurora, CO

Saturday, October 1 10:45AM - 11:10AM.

Setting the Agenda: Funding Strategies to Maximize Innovation

Garry Gibbons. NHLBI, NIH, Bethesda, MD

Saturday, October 1 11:15AM - 11:30AM.

Panel

Saturday, October 1 11:15AM - 11:30AM.

Keynote Panel

Michael R. Bristow. The University of Colorado Health, Aurora, CO

Saturday, October 1 11:15AM - 11:30AM.

Keynote Panel

Gary Gibbons. NHLBI, NIH, Bethesda, MD

Saturday, October 1 11:15AM - 11:30AM.

Keynote Panel

Bram Zuckerman. Food and Drug Administration, Bethesda, MD

Saturday, October 1 11:15AM - 11:30AM.

Keynote Panel

Mona Fiuzat. Duke University School of Medicine, Arlington, VA **Plenary 01 - Plenary**

02 - Sunday Plenary Session: Late Breaking Clinical Trials

SESSION DETAILS

Session Title: Sunday Plenary Session: Late Breaking Clinical Trials

Session Number: Plenary 02

Session Time: Sunday Oct 2, 2022 8:00 AM - 9:30 AM

Session Locations: Potomac A/B

Session Description: Late Breaking Clinical Trials is an always-popular session where speakers present the results of a new research in heart failure. Featured on a plenary session stage, Late Breaking Clinical Trials I provides exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field.

Late Breaking Clinical Trials I

- Effect Of Empagliflozin On Clinical Events In Patients Hospitalized For Acute Heart Failure: Results From EMPULSE
- Dapagliflozin In Heart Failure With Improved Ejection Fraction
- Voice Analysis-based Telemonitoring Predicts Worsening Heart Failure Events With Markedly Greater Sensitivity Than Daily Weight Monitoring
- Oral Sodium To Preserve Renal Efficiency In Acute Heart Failure (OSPNEY-AHF): A Single-center, Double-Blind, Randomized, Placebo-controlled Trial
- Effect Of Sacubitril/valsartan On Mitral Regurgitation In Heart Failure With Reduced Ejection Fraction. The PROVE-HF Study
- Blood Pressure, Dapagliflozin, And Cardiovascular Outcomes In Heart Failure With Preserved And Mildly Reduced Ejection Fraction: DELIVER

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 8:00AM - 8:00AM.

Moderator

Michael Felker. Duke University School of Medicine, Durham, NC

Sunday, October 2 8:00AM - 8:00AM.

Moderator

Debra Moser. The University of Kentucky, Lancaster, KY

Sunday, October 2 8:00AM - 8:10AM.

Effect Of Empagliflozin On Clinical Events In Patients Hospitalized For Acute Heart

Failure: Results From EMPULSE

Megan McLaughlin. University of California San Francisco, San Francisco, CA

Sunday, October 2 8:10AM - 8:15AM.

Q&A / Discussion: EMPULSE

Sunday, October 2 8:15AM - 8:25AM.

DAPAGLIFLOZIN IN HEART FAILURE WITH IMPROVED EJECTION FRACTION

Orly Vardeny. The University of Minnesota Medical School, Minneapolis, MN

Sunday, October 2 8:25AM - 8:30AM.

Q&A / Discussion: DELIVER

Sunday, October 2 8:30AM - 8:40AM.

Voice Analysis-based Telemonitoring Predicts Worsening Heart Failure Events With Markedly Greater Sensitivity Than Daily Weight Monitoring

William Abraham. The Ohio State University Wexner Medical Center, Columbus, OH

Sunday, October 2 8:40AM - 8:45AM.

Q&A / Discussion: Voice Analysis-based Telemonitoring

Sunday, October 2 8:45AM - 8:55AM.

Oral Sodium To Preserve Renal Efficiency In Acute Heart Failure (OSPNEY-AHF): A Single-center, Double-Blind, Randomized, Placebo-controlled Trial

Robert Montgomery. Cleveland Clinic Main Campus, Shaker Heights, OH

Sunday, October 2 8:55AM - 9:00AM.

Q&A / Discussion: OSPNEY-AHF

Sunday, October 2 9:00AM - 9:10AM.

Effect Of Sacubitril/valsartan On Mitral Regurgitation In Heart Failure With Reduced Ejection Fraction. The PROVE-HF Study

James Januzzi. Massachusetts General Hospital, Wellesley, MA

Sunday, October 2 9:10AM - 9:15AM.

Q&A / Discussion: PROVE-HF Study

Sunday, October 2 9:15AM - 9:25AM.

Blood Pressure, Dapagliflozin, And Cardiovascular Outcomes In Heart Failure With Preserved And Mildly Reduced Ejection Fraction: Deliver

Senthil Selvaraj. The University of Pennsylvania Health System, Durham, NC

Sunday, October 2 9:25AM - 9:30AM.

Q&A / Discussion: DELIVER

Plenary 03 - Monday Plenary Session: Xenotransplantation: Where We Are and Where We Are Going

SESSION DETAILS

Session Title: Monday Plenary Session: Xenotransplantation: Where We Are and Where We Are Going

Session Number: Plenary 03

Session Time: Monday Oct 3, 2022 8:00 AM - 9:30 AM

Session Locations: Potomac A/B

[FULL SESSION DETAILS](#) – *Speakers subject to change*

Monday, October 3 8:00AM - 8:00AM.

Moderator

Daniel Garry. The University of Minnesota Medical School, Minneapolis, MN

Monday, October 3 8:00AM - 8:00AM.

Moderator

Cheryl Westlake. Azusa Pacific University, San Clemente, CA

Monday, October 3 8:08AM - 8:18AM.

The Science and Background Enabling Xenotransplantation

Muhammad Mohiuddin. University of Maryland, Baltimore, MD

Monday, October 3 8:19AM - 8:29AM.

The First Successful Human Heart Xenotransplant

Bartley P. Griffith. University of Maryland, Baltimore, MD

Monday, October 3 8:30AM - 8:36AM.

Echocardiogram Findings

Susie Hong-Zohlman. University of Maryland, Baltimore, MD

Monday, October 3 8:37AM - 8:43AM.

Patient Selection

Susan Joseph. University of Maryland, Baltimore, MD

Monday, October 3 8:43AM - 8:53AM.

Future of Cardiac Xenotransplant: Ethical Considerations

Savitri Fedson. Baylor College of Medicine, Houston, TX

Monday, October 3 9:00AM - 9:29AM.

Panel Discussion

HOW 1 - Cardiogenic Shock

SESSION DETAILS

Session Title: Cardiogenic Shock

Session Number: HOW 1

Session Time: Saturday Oct 1, 2022 1:45 PM - 3:15 PM

Session Locations: Potomac A/B

Session Description: Cardiogenic shock confers significant morbidity and mortality. Various cardiac injuries can lead to decreased cardiac output and end-organ malperfusion. Timely recognition and initiation of appropriate inotropic and/or mechanical circulatory support is crucial to improve prognosis in cardiogenic shock. This workshop will discuss various presentations of cardiogenic shock and considerations for selecting temporary mechanical circulatory support devices as well as strategies for bridging to recovery or durable therapies (ie, LVAD, heart transplant).

[FULL SESSION DETAILS](#) – *Speakers subject to change*

Saturday, October 1 1:45PM - 1:45PM.

Lead

Kevin Alexander. Stanford University Health Care

Saturday, October 1 1:45PM - 1:45PM.

Co-Lead

Stormi Gale. Novant Health

Saturday, October 1 1:45PM - 1:45PM.

Chair - Senior Faculty

Jennifer Cowger. Henry Ford Health System

Saturday, October 1 1:45PM - 1:50PM.

Introduction

Kevin Alexander. Stanford University Health Care

Saturday, October 1 1:45PM - 1:50PM.

Introduction

Stormi Gale. Novant Health

Saturday, October 1 1:50PM - 3:10PM.

Acute Management of Cardiogenic Shock

Jennifer Cowger. Henry Ford Health System

Saturday, October 1 1:50PM - 3:10PM.

STATION 1: VA-ECMO - Case Presenter

Rola Khedraki. Scripps Clinic

Saturday, October 1 1:50PM - 3:10PM.

STATION 1: VA-ECMO - Case Discussant

Jeff Teuteberg. Stanford University Health Care, Stanford, CA

Saturday, October 1 1:50PM - 3:10PM.

STATION 2: Left-sided MCS (Tandem Heart) - Case Presenter

Sabra Lewsey. Johns Hopkins University School of Medicine

Saturday, October 1 1:50PM - 3:10PM.

STATION 2: Left-sided MCS (Tandem Heart) - Case Discussant

Garrick Stewart. Mass General Brigham

Saturday, October 1 1:50PM - 3:10PM.

STATION 3: CentriMag/BiVAD - Case Presenter

Onyedika Ilonze. Indiana University Health

Saturday, October 1 1:50PM - 3:10PM.

STATION 3: CentriMag/BiVAD - Case Discussant

Sean Pinney. The University of Chicago Health, Wyckoff, NJ

Saturday, October 1 1:50PM - 3:10PM.

STATION 4: RVAD (ProtekDuo) - Case Presenter

Sunit-Preet Chaudhry. Ascension Medical Group

Saturday, October 1 1:50PM - 3:10PM.

STATION 4: RVAD (ProtekDuo) - Case Discussant

Rhondalyn McLean. The University of Pennsylvania Health System, Philadelphia, PA

Saturday, October 1 1:50PM - 3:10PM.

Closing Remarks

Jennifer Cowger. Henry Ford Health System

HOW 2 - CPET Basics

SESSION DETAILS

Session Title: CPET Basics

Session Number: HOW 2

Session Time: Sunday Oct 2, 2022 9:45 AM - 11:15 AM

Session Locations: Potomac 4/5

Session Description: The role of cardiopulmonary exercise testing in the evaluation of patients with cardiovascular disease continues to increase. Research has long demonstrated that CPET can provide important prognostic information in both patients with HFrEF and HFpEF. Newer data highlight important subtleties in cardiopulmonary physiology that may uncover unrecognized pathology in certain patients and even lead to novel treatment strategies, particularly when coupled with invasive hemodynamic assessment. Data is also emerging about the role of CPET in surgical and device-based HF treatment. Finally, CPET can be pivotal in the evaluation of patients with unexplained dyspnea by distinguishing the relative contributions of pulmonary, cardiac, and peripheral limitations to exercise. Many such patients are seen by heart failure cardiologists as part of their workup. It is clear that a thorough understanding of exercise physiology and interpretation of CPET is critical to the early career heart failure provider. This workshop will review practical aspects of CPET performance and interpretation, with a goal of providing attendees with hands-on, practical experience and actionable information that can help them develop or broaden the use of CPET in their own practice and increase their confidence in interpreting results.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 9:45AM - 9:45AM.

Lead

Gaurav Gulati. Tufts Medical Center, Boston, MA

Sunday, October 2 9:45AM - 9:45AM.

Chair - Senior Faculty

Ryan Tedford. Medical University of South Carolina Health, Charleston, SC

Sunday, October 2 9:45AM - 9:50AM.

Introduction

Gaurav Gulati. Tufts Medical Center, Boston, MA

Sunday, October 2 9:50AM - 10:05AM.

CPET Basics

Gregory Lewis. Massachusetts General Hospital, Boston, MA

Sunday, October 2 10:05AM - 10:15AM.

Station 1: Setting up the CPET - Case Presenter

Onyedika Ilonze. Indiana University Health, Indianapolis, IN

Sunday, October 2 10:15AM - 10:25AM.

Station 1: Setting up the CPET - Mid/Senior Faculty

Jessica Yorkdale. Inova Health System, Falls Church, VA

Sunday, October 2 10:25AM - 10:35AM.

Station 2: Demystifying the 9-plot - Case Presenter

Yasmin Raza. Northwestern University Feinberg School of Medicine, Chicago, IL

Sunday, October 2 10:35AM - 10:45AM.

Station 2: Demystifying the 9-plot - Mid/Senior Faculty

Roopa Rao. Indiana University Health, Carmel, IN

Sunday, October 2 10:45AM - 10:55AM.

Station 3: Taking CPET to the next level with invasive hemodynamics - Case Presenter

Gaurav Gulati. Tufts Medical Center, Newtonville, MA

Sunday, October 2 10:55AM - 11:05AM.

Station 3: Taking CPET to the next level with invasive hemodynamics - Mid/Senior Faculty

Sula Mazimba. The University of Virginia Health System (Advanced Heart Failure and Transplant Center), Charlottesville, VA

Sunday, October 2 11:05AM - 11:15AM.

Wrap-up, Q&A, Panel Discussion

Gaurav Gulati. Tufts Medical Center, Boston, MA

HOW 3 - How to Manage and Monitor Patients with VADs: Alarms and PA Pressure Monitors

SESSION DETAILS

Session Title: How to Manage and Monitor Patients with VADs: Alarms and PA Pressure Monitors

Session Number: HOW 3

Session Time: Sunday Oct 2, 2022 2:15 PM - 3:45 PM

Session Locations: Potomac 4/5

Session Description: Temporary and durable mechanical circulatory support (MCS) remain an integral treatment resource for patients suffering from advanced heart failure and cardiogenic shock. Clinical assessment and troubleshooting of MCS equipment both at the bedside and at home is essential for the advanced heart failure practitioner. Recent advances in remote monitoring now provide additional tools for monitoring of these complex patients. This session's focus will be to work through four clinical scenarios related to LVAD care remotely and at the bedside.

Each fifteen-minute break out session will begin with a case presentation by an early to mid-career faculty, with two targeted stop points to facilitate audience Q&A. During the Q&A, the mid to senior faculty will be given time to engage with audience to discuss diagnostic/therapeutic algorithm and expert opinion.

FULL SESSION DETAILS – *Speakers subject to change*

Sunday, October 2 2:15PM - 2:15PM.

Lead

Faraz Ahmad. Northwestern Medicine, River Forest, IL

Sunday, October 2 2:15PM - 2:15PM.

Chair

Maryjane Farr. UT Southwestern Medical Center, Dallas, TX

Sunday, October 2 2:15PM - 2:20PM.

Introduction and Orientation

Faraz Ahmad. Northwestern Medicine, River Forest, IL

Sunday, October 2 2:20PM - 2:30PM.

Opening Remarks: How to Manage and Monitor Patients with VADs: Alarms and PA pressure monitors

Maryjane Farr. UT Southwestern Medical Center, Dallas, TX

Sunday, October 2 2:30PM - 3:40PM.

Station 1: LVAD Pump Thrombosis

Ashley Young. George Washington University Hospital, Washington, DC, DC

Sunday, October 2 2:30PM - 3:40PM.

Station 1: LVAD Pump Thrombosis

Albert Hicks. Houston Methodist Health, Towson, MD

Sunday, October 2 2:30PM - 3:40PM.

Station 2: Low Flow Alarms

Claudio Bravo. University of Washington, Seattle, WA

Sunday, October 2 2:30PM - 3:40PM.

Station 2: Low Flow Alarms

Melana Yuzefpolskaya. New York, NY

Sunday, October 2 2:30PM - 3:40PM.

Station 3: LVAD Code/Resuscitation

Katelyn Hilborn. Acesnsion, Nashville, TN

Sunday, October 2 2:30PM - 3:40PM.

Station 3: LVAD Code/Resuscitation

Roopa Rao. Indiana University Health, Carmel, IN

Sunday, October 2 2:30PM - 3:40PM.

Station 4: CardioMEMs in the LVAD patient

Ankit Bhatia. The Christ Hospital Health Network, Cincinnati, OH

Sunday, October 2 2:30PM - 3:40PM.

Station 4: CardioMEMs in the LVAD patient

Gabriel Sayer. Columbia University, New York, NY

Sunday, October 2 3:40PM - 3:45PM.

Closing Remarks

Faraz Ahmad. Northwestern Medicine, River Forest, IL

HOW 4 - Monitoring of Heart Transplant Rejection

SESSION DETAILS

Session Title: Monitoring of Heart Transplant Rejection

Session Number: HOW 4

Session Time: Monday Oct 3, 2022 9:45 AM - 11:00 AM

Session Locations: Potomac 4/5

Session Description: The monitoring and management of rejection in transplanted hearts is an important component of advanced heart failure clinical care. In recent years, there has been increased interest in non-traditional means of surveillance for rejection. This hands-on workshop aims to teach participants about alternative methods to endomyocardial biopsy for rejection monitoring – both non-invasive (gene expression profiling and donor derived cell free DNA) and invasive (molecular microscope biopsies).

FULL SESSION DETAILS – *Speakers subject to change*

Monday, October 3 9:45AM - 9:45AM.

Lead

Megan Fraser. The University of Minnesota Physicians, Mendota Heights, MN

Monday, October 3 9:45AM - 9:45AM.

Chair - Senior Faculty

Jon Kobashigawa. Cedars-Sinai Medical Center, Los Angeles, CA

Scientific Session Information



Monday, October 3 9:45AM - 9:50AM.

Introduction

Megan Fraser. The University of Minnesota Physicians, Mendota Heights, MN

Monday, October 3 9:50AM - 10:00AM.

Liquid Biopsy - Future of Transplant Management

Jon Kobashigawa. Cedars-Sinai Medical Center, Los Angeles, CA

Monday, October 3 10:00AM - 10:35AM.

Station 1. Case Examples with Gene Expression Profiling - Case Presenter

Amit Patel. Indianapolis, IN

Monday, October 3 10:00AM - 10:35AM.

Station 1. Case Examples with Gene Expression Profiling - Mid/Senior Faculty

Laura Peters. The University of Colorado Health, Denver, CO

Monday, October 3 10:00AM - 10:35AM.

Station 2. Case Examples with Donor Derived Cell Free DNA - Case Presenter

Naveen Bellam. Advent Health Transplant Institute, Orlando, FL

Monday, October 3 10:00AM - 10:35AM.

Station 2. Case Examples with Donor Derived Cell Free DNA - Mid/Senior Faculty

Amanda Vest. Tufts Medical Center, Boston, MA

Monday, October 3 10:00AM - 10:35AM.

Station 3. Molecular Microscope Biopsy Acquisition and Result Interpretation - Case Presenter

Jessica Schultz. The University of Utah Health, Salt Lake City, UT

Monday, October 3 10:00AM - 10:35AM.

Station 3. Molecular Microscope Biopsy Acquisition and Result Interpretation - Mid/Senior Faculty

Cindy Martin. The University of Minnesota Physicians, Minneapolis, MN

Monday, October 3 10:35AM - 10:50AM.

Audience Q&A / Panel Discussion

Scientific Session Information



Monday, October 3 10:35AM - 10:50AM.

Audience Q&A / Panel Discussion - Additional Panelist

Olga Timofeeva. 1

Monday, October 3 10:50AM - 11:00AM.

Closing Remarks

Jon Kobashigawa. Cedars-Sinai Medical Center, Los Angeles, CA